Stockwinners Market Radar for May 03, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
PACB | Hot Stocks20:32 EDT Cathie Wood's ARK Investment bought 564K shares of Pacific Biosciences today
|
SAN | Hot Stocks18:45 EDT Banco Santander raises prime rate to 8.25% from 8.00%, effective May 3
|
WING | Hot Stocks18:21 EDT Wingstop CEO: There's a ton of growth in our brand right now - In an interview on CNBC's Mad Money, Michael Skipworth said Wingstop has several unique growth levers at the company. It's bringing a ton of new guests to the brand, he noted. He sees expansion in the delivery channel and a lift in the average check. Brand partners are seeing their strongest cash flows in some time. He sees a favorable commodity backdrop for 2023.
|
HSBC | Hot Stocks18:12 EDT HSBC raises prime rate to 8.25% from 8.00%, effective tomorrow
|
LGIH | Hot Stocks18:11 EDT LGI Homes reports 557 homes closed in April - LGI Homes announced it closed 557 homes in April 2023. As of April 30, 2023, the Company had 103 active selling communities.
|
PAC | Hot Stocks18:06 EDT GAP Airports reports April passenger traffic up 15.2% y/y - GAP Airports announced preliminary terminal passenger traffic figures for the month of April 2023, compared with the same period of 2022. For April 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 15.1%, compared to the same period in 2022. Guadalajara, Tijuana, Puerto Vallarta, and Los Cabos presented an increase in passenger traffic of 18.6%, 13.8%, 12.4%, and 11.6% respectively, compared to April 2022. On the other hand, Montego Bay increased by 13.0% and Kingston by 25.7%, compared to 2022.
|
GTE | Hot Stocks18:03 EDT Gran Tierra announces1-for-10 reverse stock - Gran Tierra Energy announced that at its annual meeting of stockholders held on May 3, the company's stockholders have approved a 1-for-10 reverse stock split of the company's common stock, par value $0.01 per share. The reverse stock split was previously approved by the company's board of directors in February 2023, subject to shareholder approval.
|
ALPMY | Hot Stocks18:01 EDT Astellas Pharma's treatment of gastric cancer granted FDA orphan designation - According to a post on the FDA's website, Astellas Pharma's treatment of gastric cancer was granted orphan designation. Reference Link
|
BLNK | Hot Stocks18:00 EDT Blink Charging names Brendan Jones as CEO - The Board of Directors of Blink Charging announced that Brendan S. Jones has been promoted to the role of President and Chief Executive Officer for Blink Charging. Michael D. Farkas will continue to serve on the board. Mr. Jones joined Blink in April 2020 as the Company's Chief Operating Officer and has been serving as its President since 2021 where he has successfully positioned the organization for future expansion.
|
PYXS | Hot Stocks17:58 EDT Pyxis Oncology's treatment of pancreatic cancer granted FDA orphan designation - According to a post on the FDA's website, Pyxis Oncology's treatment of pancreatic cancer was granted orphan designation. Reference Link
|
GVA | Hot Stocks17:57 EDT Granite awarded $172.95M Army contract - Granite was awarded a $172.95M firm-fixed-price contract for the Sacramento Weir Widening project. Bids were solicited via the internet with three received. Work will be performed in West Sacramento, California, with an estimated completion date of October 15, 2026. FY23 civil construction funds in the amount of $172.95M were obligated at the time of the award. U.S. Army Corps of Engineers is the contracting activity.
|
ASNS | Hot Stocks17:56 EDT Actelis Networks regains compliance with Nasdaq - Actelis Networks announced that it received notice from The Nasdaq Stock Market (Nasdaq) on May 3 that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for maintaining the listing of the shares of the company's common stock on the Nasdaq Global Capital Market.
|
SLNO | Hot Stocks17:55 EDT Soleno Therapeutics completes enrollment in withdrawal period of Study C602 - Soleno Therapeutics announced that it has completed enrollment in the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome, or PWS. The FDA previously acknowledged that data from the study has the potential to support a New Drug Application, or NDA, submission for DCCR.
|
ADBE | Hot Stocks17:52 EDT Adobe exec sells $1.12M in common stock - In a regulatory filing, Adobe disclosed that its EVP of Creative Cloud, Scott Belsky, sold 3K shares of common stock on May 2nd in a total transaction size of $1.12M.
|
WBS | Hot Stocks17:50 EDT Webster Financial raises prime lending rate to 8.25% from 8% - Webster Financial Corporation announced that it has raised its prime lending rate to 8.25% from 8%, effective May 4, 2023.
|
NTRS | Hot Stocks17:49 EDT Northern Trust raises prime rate to 8.25% from 8.00%, effective May 4
|
DCO | Hot Stocks17:47 EDT Ducommun appoints Suman Mookerji as CFO - Ducommun announced the appointment of Suman Mookerji, the company's current vice president, corporate development & investor relations to senior vice president, chief financial officer, controller & treasurer. Suman will also continue to lead the corporate development function at the company. Christopher Wampler, Ducommun's former vice president, chief financial officer, controller & treasurer will continue his employment with the company in a non-executive capacity to facilitate a smooth transition of responsibilities.
|
ABNB | Hot Stocks17:46 EDT Airbnb debuts Airbnb Rooms amid push for less expensive accomodations - Airbnb's 2023 Summer Release, introduces Airbnb Rooms, "an all-new take on the original Airbnb." The company said in part: "With the pandemic finally over, this year we're expecting over 300 million guest arrivals on Airbnb.. Now is the perfect time to stay in a room in someone else's home. But for even more people to try it, they have to feel comfortable staying with a Host We're introducing Airbnb Rooms, an all-new take on the original Airbnb. Guests have told us that they want to know more about who they're staying with. Every Airbnb Room features a Host Passport, which helps guests get to know their Host before booking their stay. We've also created a Rooms category with over 1 million listings, redesigned filters and added new privacy features." some of the new features include Host Passport - We want every guest to feel comfortable staying with a Host. Exclusive to Airbnb Rooms, the Host Passport helps you get to know your Host before booking your stay. ..Airbnb Rooms are easy to discover, with a new category featuring a curated set of 1 million private bedrooms. Listings include access to shared spaces, like the kitchen, living room, or backyard. Redesigned filters - We've redesigned the "type of place" filter to make it easy to switch between Airbnb Rooms, entire homes, or all types of places...New privacy features - We know that when you're sharing a home, privacy is important. All Airbnb Rooms will clearly indicate if the bedroom door has a lock. The listing page also shows whether the bathrooms are shared or private, and whether people other than the Host will be in the home during your stay." Reference Link
|
TGR | Hot Stocks17:43 EDT Kimbell Tiger Acquisition to redeem public shares - Kimbell Tiger Acquisition announced that it will redeem all of its outstanding shares of Class A Common Stock included as part of the units issued in its initial public offering and the 2,500 shares of Class A common stock forming part of the sponsor shares, effective as of the close of business on May 22, as the company will not consummate an initial business combination on or prior to May 8. Based on the amount held in trust as of March 31, the per-share redemption price for the public shares will be approximately $10.56. The public shares will cease trading as of the close of business on May 8. As of the close of business on May 9, the public shares will be deemed cancelled and will represent only the right to receive the redemption amount.
|
GIFI | Hot Stocks17:42 EDT Gulf Island Fabrication awarded up to $10M contract to support ML2 project - Gulf Island Fabrication announced that it has been awarded a fabrication contract by Bechtel National to support the Mobile Launcher 2, or ML2, project. Gulf Island will be fabricating structural components for the ML2 project at its Houma fabrication facility for delivery to the project site at the Kennedy Space Center. The contract has an estimated value of less than $10M and will be included in the company's new awards and backlog in the second quarter 2023.
|
TGR | Hot Stocks17:42 EDT Kimbell Tiger Acquisition to redeem public shares - Kimbell Tiger Acquisition announced that it will redeem all of its outstanding shares of Class A Common Stock included as part of the units issued in its initial public offering and the 2,500 shares of Class A common stock forming part of the sponsor shares, effective as of the close of business on May 22, as the company will not consummate an initial business combination on or prior to May 8.
|
NS | Hot Stocks17:41 EDT NuStar Energy, OCI Global sign agreement to deliver ammonia into Midwest - NuStar Energy's and OCI Global's affiliates have entered into an agreement for OCI Global to transport ammonia on a new segment of NuStar Pipeline Operating Partnership's Ammonia Pipeline System. Under the arrangement, NuStar will install a new 14-mile pipeline segment that will connect OCI's Nitrogen facility in Wever, Iowa with NuStar's existing 2,000-mile anhydrous ammonia pipeline, which originates in Louisiana and flows northbound to various points in the Midwest, including Iowa. OCI's facility uses ammonia to make fertilizer and produce Diesel Exhaust Fluid, which reduces emissions from diesel engines in cars, as well as light and heavy-duty trucks, farming equipment and other heavy machinery.
|
LECO | Hot Stocks17:40 EDT Lincoln Electric acquires Powermig Automacao e Soldagem, terms undisclosed - Lincoln Electric announced that it has acquired Powermig Automacao e Soldagem, a privately held automation engineering firm headquartered in Caxias do Sul, Rio Grande do Sul state, in Brazil. Powermig specializes in designing and engineering industrial welding automation solutions for the heavy industry and transportation sectors and has an annual revenue of approximately $15M.
|
STE | Hot Stocks17:31 EDT Steris announces new $500M share buyback program - Steris announced that Steris board of directors has authorized a new share buyback program for the purchase of up to $500M of the company's ordinary shares. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time.
|
USB | Hot Stocks17:31 EDT U.S. Bancorp raises prime lending rate to 8.25% from 8.00%, effective May 4 - The reference rate at all Union Bank locations will also increase to 8.25% from 8.00% on May 4.
|
NBIX | Hot Stocks17:30 EDT Neurocrine chief HR officer Cooke sells 11,397 common shares - In a regulatory filing, Neurocrine Biosciences chief HR officer Julie Cooke disclosed the sale of 11,397 common shares of the company on May 1 at a price of $103.8913 per share.
|
MOS | Hot Stocks17:30 EDT Mosaic sees 2023 CapEx $1.3B-$1.4B - Grain and oilseed markets are expected to remain tight through 2023 and likely beyond. The disruption to Ukraine's agricultural production caused by war, coupled with reduced fertilization and sub-optimal weather in major growing regions like the Americas, Europe and China, threaten global agricultural production. This suggests that global stocks-to-use ratios, already projected at 25-year lows, will remain under pressure. Historically elevated crop prices coupled with fertilizer pricing that has moderated from the post-Ukraine-invasion spike justifies a return to normal nutrient applications. In North America, sentiment has improved significantly from the second half of 2022, and spring nutrient application rates are trending toward normal levels. In Brazil, an attractive fertilizer-to-soybean barter ratio suggests a significant recovery in fertilizer shipments in 2023. For both potash and phosphates, supply constraints remain. In potash, we expect annual shipments from Belarus will be down 5-6 million tonnes from pre-sanction export rates. In phosphates, China's exports are expected to see only a modest recovery from the recent lows in 2022 but remain well below shipments seen in 2021. In both phosphates and potash, the fundamental tightness in global markets is expected to persist well into 2023 and likely beyond.
|
BLNK | Hot Stocks17:27 EDT Blink Charging CEO Michael Farkas to leave role, Brendan Jones to succeed - The board of directors of Blink Charging announced that Brendan Jones has been promoted to the role of CEO and president of Blink Charging. Michael Farkas will continue to serve on the board. Jones joined Blink in April 2020 as the company's COO and has been serving as its president since 2021. Farkas, the founder of Blink Charging, served as its CEO and executive chairman and in other executive management positions since 2009.
|
DB | Hot Stocks17:22 EDT Deutsche Bank raises prime lending rate to 8.25% from 8.00%, effective May 4
|
NOVA | Hot Stocks17:15 EDT Sunnova Energy teams with Amica Insurance to expand energy services - Sunnova Energy International announced it is teaming up with Amica Insurance to expand the reach of Sunnova's clean, affordable, and reliable energy services. Sunnova and Amica will work together to offer energy services to Amica's customers, as well as wide-ranging insurance products to Sunnova's customers, to provide a combined solution of clean energy and insurance to homeowners across the U.S. "At Amica, we're committed to helping our customers find solutions that meet their unique needs. Through this partnership with Sunnova, our customers and employees across the country now have access to innovative and reliable solar energy services like solar, battery storage, energy control and other hardware, and software technologies that will help them cut energy costs and reduce their carbon footprints," said Yiguang Qiu, Senior Assistant Vice President, Marketing & Communications, Amica. "This collaboration is a testament to our shared commitment of providing exceptional customer service and building strong, long-lasting relationships. With Sunnova, we're driving innovation and delivering greater value to our customers and employees."
|
CFG | Hot Stocks17:15 EDT Citizens Bank raises prime lending rate to 8.25% from 8% - Citizens Financial Group announced that Citizens Bank, N.A. has raised its prime lending rate to 8.25% from 8%, effective Thursday, May 4, 2023.
|
AAT | Hot Stocks17:15 EDT American Assets Trust CEO buys $5.69M in common stock in option exercise - In a regulatory filing, American Assets Trust disclosed that its CEO Ernest Rady bought 320K shares of common stock on May 1st with total value of $5.69M as part of an option exercise.
|
COST | Hot Stocks17:10 EDT Costco reports April sales of $17.85B - Reports April comparable sales up 1.4%. Reports April e-commerce sales down 5.9%.
|
VRTX | Hot Stocks17:08 EDT Vertex announces FDA approval for KALYDECO to treat eligible infants with CF - Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration approved KALYDECO for use in children with cystic fibrosis ages 1 month to less than four months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S. and EU for the treatment of CF in patients ages four months and older. "Treating the underlying cause of cystic fibrosis as early as possible is important, and this approval, the first for a CFTR modulator in this age group, means families will now have a medicine for eligible infants," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.
|
BTBT BTC | Hot Stocks17:07 EDT Bit Digital reports April Bitcoin production - In April 2023, the company earned 86.1 Bitcoins (BTC), a 28% decrease compared to the prior month. The decrease in production was primarily driven by the relocation of approximately 6,500 mining units from facilities previously operated by Compute North to different hosting sites that commenced during the month, and to a lesser extent, an increase in the bitcoin network difficulty. 11,513 bitcoin miners representing 1.20 EH/s, was actively hashing in North America as of April 30, 2023. Treasury holdings of BTC and ETH were 553.2 and 9,900.9 with a fair market value of approximately $16.2M and $18.6M, respectively, on April 30. The BTC equivalent of digital asset holdings as of April 30 was approximately 1,558.3, or approximately $45.5M. The company had cash and cash equivalents of $21.9M as of April 30, 2023.
|
BHG | Hot Stocks17:01 EDT Bright Health names Jay Matushak CFO - Bright Health Group announced that it has appointed Jay Matushak as the Company's next Chief Financial Officer, effective May 12, 2023. Matushak will succeed Cathy Smith, who is stepping down to pursue another opportunity. Matushak, a seasoned finance and operational executive with deep expertise in the healthcare business, joined Bright Health in 2021. Smith will continue in her role through the company's first quarter 2023 earnings and thereafter will serve in an advisory role to support a smooth transition. Smith's decision to resign was not due to any conflicts with the Board or management team regarding the company's financial reporting or accounting principles or practices.
|
AMED | Hot Stocks17:00 EDT Amedisys trading resumes
|
PRMW | Hot Stocks16:59 EDT Primo Water signs agreement with Legion Partners - Primo Water has entered into a cooperation agreement with Legion Partners. Following the Annual Meeting, the size of Primo Water's Board of Directors will revert to ten directors. Primo Water will appoint two new independent directors nominated by Legion, Derek Lewis and Lori Tauber Marcus, who will join Primo Water's Board of Directors on May 3, and will also nominate Lewis and Marcus for election to the Board at the company's 2023 annual and special meeting of shareowners to be held on May 31. In addition, the company has agreed to adopt certain corporate governance enhancements, including changes to its advance notice bylaw provisions. In connection with the appointment of these two new directors, Legion has withdrawn its notice of intention to nominate candidates for election at the Annual Meeting and has agreed to customary standstill and voting commitments. Legion has also agreed not to pursue its complaints to the Ontario Securities Commission and the Toronto Stock exchange in connection with the Annual Meeting.
|
PACW | Hot Stocks16:57 EDT PacWest selloff continues, shares down 49% to $3.30
|
IOSP | Hot Stocks16:57 EDT Innospec boosts semi-annual dividend by 10% - This quarter, the Innospec board approved a further 10% increase in its semi-annual dividend to 69c per share.
|
CBOE | Hot Stocks16:57 EDT Cboe Global Markets reports April trading volume - Reference Link
|
RF | Hot Stocks16:54 EDT Regions Bank raises prime lending rate to 8.25% from 8% - Regions Bank announced it is increasing the Regions prime lending rate to 8.25% from 8.00%, effective Thursday, May 4, 2023.
|
C | Hot Stocks16:54 EDT Citibank raises base lending rate to 8.25% from 8% - Citibank, N.A. said it has raised its base lending rate to 8.25% from 8.00%, effective tomorrow, Thursday, May 4, 2023.
|
CPE | Hot Stocks16:54 EDT Callon Petroleum to acquire core Delaware Basin assets, exit Eagle Ford - Callon Petroleum signed two definitive agreements that streamline and focus Callon's operations, accelerate the achievement of its debt reduction target and allow for the initiation of a shareholder return program in the third quarter of 2023. Callon has entered into a definitive agreement to acquire the membership interests of Permian-based Percussion Petroleum Operating II in a cash and stock transaction valued at approximately $475M and potential contingent payments of up to $62.5M. Under the terms of the agreement, Percussion will receive $265M of cash and a maximum of 6.46M shares of Callon common stock. The transaction is structured as the acquisition by Callon Petroleum Operating Company of 100% of the limited liability company interests of Percussion. Under a separate agreement, Callon agreed to sell all its assets in the Eagle Ford Shale to Ridgemar Energy Operating for $655M in cash and potential contingent payments of up to $45M. The transaction is structured as the acquisition by Ridgemar of 100% of the limited liability company interests of Callon's wholly owned subsidiary Callon LLC. The transactions are subject to customary terms and conditions and are expected to simultaneously close in July 2023, both with an effective date of January 1, 2023.
|
WFC | Hot Stocks16:54 EDT Wells Fargo Bank raises prime rate to 8.25% from 8% - Wells Fargo Bank said it is increasing its prime rate to 8.25% from 8%, effective tomorrow, May 4, 2023.
|
CHRD | Hot Stocks16:53 EDT Chord Energy sees 2023 total volumes 163.2- 68.2 MBoepd
|
EXP | Hot Stocks16:53 EDT Eagle Materials completes acquisition of Martin Marietta cement import business - Eagle Materials (EXP) "announced it has completed the acquisition of Martin Marietta's (MLM) cement import and distribution business in Northern California, which includes its cement terminal in Stockton, California. The acquisition is consistent with the company's strategic intentions to extend and strengthen its distribution reach across its heartland US cement manufacturing system."
|
ASB | Hot Stocks16:52 EDT Associated Banc-Corp increases prime rate to 8.25% from 8.00%, effective May 3
|
SUM | Hot Stocks16:49 EDT Summit Materials raises 2023 adjusted EBITDA view to $490M-$530M - Up from previous outlook of $480M-$520M. Summit currently projects 2023 capital expenditures of approximately $220 million to $240 million including greenfield projects.
|
PACW | Hot Stocks16:49 EDT PacWest sinks 24% to $4.91 after Bloomberg report on strategic options
|
PNC | Hot Stocks16:49 EDT PNC Financial raises prime lending rate to 8.25%, effective May 4
|
FARO | Hot Stocks16:48 EDT Faro Technologies CEO Michael Burger to retire, Yuval Wasserman interim CEO - Faro Technologies announced that Michael Burger has informed the company that he intends to retire as president & CEO and such retirement will be effective July 1. The board of directors has appointed Yuval Wasserman, its current chairman of the board as Executive Chairman effective May 4th, and as Chairman and Interim CEO, effective July 1. Burger will remain as a strategic advisor to the company and to Wasserman, to assist in the transition. Yuval Wasserman was previously President CEO of Advanced Energy Industries from 2014 to 2021.
|
HOUS | Hot Stocks16:46 EDT Anywhere Real Estate sees Q2 transaction volume down 25% vs. last year - Still expects quarterly transaction volume comparisons to 2022 to improve throughout 2023, but expects full year 2023 transaction volumes to decline about 15-20% year-over-year. Driven by these projected volume declines, the company continues to expect full year 2023 Operating EBITDA to be below 2022. However, the company still expects Free Cash Flow from operations to be modestly positive. Continues to expect to realize cost savings of approximately $200 million in 2023, inclusive of the cost savings realized in 1Q23.
|
COF | Hot Stocks16:45 EDT Capital One urges shareholders to reject mini-tender offer by TRC Capital - Capital One Financial has been notified of an unsolicited mini-tender offer by TRC Capital Investment to purchase up to 1,500,000 shares of COF common stock, representing less than one percent of COF's common stock outstanding. The offering price of $93.47 per share is 4.46 percent below the closing price per share of COF's common stock on April 17, the last trading day prior to the date of the offer, April 18. The company recommends that common stockholders who have not responded to TRC's offer take no action. COF common stockholders who have already tendered their shares may withdraw their shares by providing the written notice described in the TRC offering documents prior to the expiration of the offer, currently scheduled for 12:01 a.m., New York City Time on May 17. The company further recommends that stockholders do not tender their shares in response to TRC's offer because the offer is subject to numerous conditions, including TRC obtaining financing for the offer. There is no guarantee the conditions of the offer will be satisfied.
|
APA | Hot Stocks16:45 EDT APA Corp. lowers FY upstream capital investment guidance to $1.9B-$2B - APA is lowering full-year upstream capital investment guidance to $1.9- to $2.0 billion, with the entire $100 million decrease attributable to the reduction of lean gas activity in the Permian Basin. This change is not expected to have a material impact on 2023 U.S. production. Other capital activity for the year is unchanged, as the company plans to continue running an average of 17 drilling rigs in Egypt and five in the U.S. As previously disclosed, APA will release the Ocean Patriot semisubmersible drilling rig in the North Sea around midyear.
|
KNTK | Hot Stocks16:41 EDT Kinetik sees FY23 CapEx at upper end of $490M-$540M range
|
HCC | Hot Stocks16:40 EDT Warrior Met Coal sees FY23 coal sales 6.6M-7.2M short tons - Sees FY23 Coal production 6.3 - 6.9 million short tons; Cash cost of sales (free-on-board port) $109 - $125 per short ton; and Capital expenditures for existing mines $95M - $105M.
|
AMOT | Hot Stocks16:39 EDT Allied Motion raises quarterly dividend 20% to 3c per share - Allied Motion announced that its Board of Directors approved a quarterly cash dividend payment of $0.03 per share, up 20% from the previous rate of $0.025 per share. The dividend will be payable on June 1, 2023 to stockholders of record as of the close of business on May 18, 2023. Dick Warzala, Chairman and CEO, commented, "This dividend increase reflects our confidence in our strategy, strong financial position and positive long-term view of the markets we serve."
|
QTWO | Hot Stocks16:36 EDT Q2 Holdings names Kirk Coleman president - Q2 Holdings announced that Kirk Coleman has been promoted to President. In this role, Coleman will lead sales, marketing, product, engineering and operations for the company. He will continue to report directly to Matt Flake, Q2's Chief Executive Officer. "Kirk brings a wealth of experience, expertise and leadership to our executive team," said Q2 CEO Matt Flake. "This business has always been built on innovating, delivering and supporting great products for our customers, and Kirk's deep understanding of the financial services industry and banking operations make him the perfect candidate to drive those aspects of our business day to day." These changes take effect immediately.
|
OPCH AMED | Hot Stocks16:35 EDT Option Care Health acquires Amedisys for $3.6B in all-stock transaction - Option Care Health (OPCH) and Amedisys (AMED) announced that they have entered into a definitive merger agreement to combine in an all-stock transaction that values Amedisys at approximately $3.6B, including the assumption of net debt. Under the terms of the agreement, Amedisys stockholders will receive 3.0213 shares of Option Care Health common stock for each share of Amedisys common stock they hold at the closing of the transaction, the equivalent of $97.38 per Amedisys share based on Option Care Health's closing stock price on May 2. This represents an approximate 26% premium to Amedisys stockholders based on the closing stock price of Amedisys on May 2. Upon closing Option Care Health stockholders will own approximately 64.5% of the combined company, and Amedisys stockholders will own approximately 35.5%. John Rademacher and Mike Shapiro will continue to lead the combined company in their roles as CEO and CFO, respectively. The transaction is expected to close in the second half of 2023, subject to approval by Option Care Health and Amedisys stockholders and other customary closing conditions. The transaction was approved by the boards of both companies.
|
RGNX | Hot Stocks16:35 EDT Regenxbio sees cash, cash equivalents, securities sufficient into 2025
|
MRO | Hot Stocks16:33 EDT Marathon Oil backs FY23 CapEx view $1.9B-$2B - Marathon Oil's originally provided 2023 production guidance remains unchanged, as does the Company's 2023 capital spending guidance range of $1.9B-$2B, with approximately 60% of 2023 capital spending weighted to the first half of the year.
|
CIVI | Hot Stocks16:30 EDT Civitas Resources sees FY23 total production 160-170 MBoe/d - Sees FY23 oil production 72-77 MBoe/d.
|
CIVI | Hot Stocks16:29 EDT Civitas Resources board approves dividend of $2.12 per share - The company's board of directors approved a dividend of $2.12 per share, payable on June 29, 2023 to shareholders of record as of June 15, 2023. The total reflects the combination of a quarterly base dividend of $0.50 per share and a quarterly variable dividend of $1.62 per share.
|
AMED | Hot Stocks16:27 EDT Amedisys trading halted, news pending
|
DEN | Hot Stocks16:26 EDT Denbury sees Q2 sales volumes similar to Q1 - Second quarter 2023 sales volumes are anticipated to be similar to the first quarter based on increased production associated with the commencement of the CCA EOR flood, along with new production from the Charles development wells at CCA, primarily offset by a planned Delhi facility turnaround and the timing of inventory sales at Tinsley. Associated with the startup and ramp of EOR production at CCA, the Company anticipates DD&A and LOE per BOE to increase from first quarter levels, driven by the expected recording of initial tertiary reserves at CCA and the conversion of CO2 injection to LOE rather than capital. Second quarter 2023 capital expenditures are anticipated to be modestly higher than the first quarter of the year, led by CCUS capital expenditures, which should increase based on CO2 storage site acquisition and pre-development spend. Oil & gas development capital is expected to be at similar levels as the first quarter of the year.
|
VET | Hot Stocks16:25 EDT Vermilion Energy still sees 2023 production average 82,000-86,000 boe/d
|
UGI | Hot Stocks16:25 EDT UGI Corporation raises quarterly dividend 4.2% to 37.5c per share - The Board of Directors of UGI Corporation declared a quarterly dividend of $0.375 per share of the Company's common stock, representing a 4.2% increase. The dividend is payable July 1, 2023, to shareholders of record as of June 15, 2023. Roger Perreault, President and Chief Executive Officer of UGI, said, "We are pleased to mark the 36th consecutive year of increasing dividends, building on our long history of delivering returns to shareholders while investing for continued growth. This consistency demonstrates the strength and resilience of UGI and its capital allocation strategy as we seek to create shareholder value as both a growth and income investment." UGI's Board of Directors also declared a quarterly dividend of 0.125% per annum, payable in cash, on the Company's convertible preferred stock. The dividend is payable June 1, 2023.
|
ALLO | Hot Stocks16:25 EDT Allogene Therapeutics sees decrease in cash/equivalents of $230M in FY23 - The Company now expects a decrease in cash, cash equivalents, and investments of approximately $230M in 2023. Based on current expectation, the Company expects its cash runway to be sufficient to fund operations into Q2 2025. GAAP Operating Expenses are expected to be approximately $340M including estimated non-cash stock-based compensation expense of approximately $80M. These estimates exclude any impact from potential business development activities.
|
VET | Hot Stocks16:24 EDT Vermilion Energy sees Q2 production average 84,000-86,000 boe/d
|
WERN | Hot Stocks16:23 EDT Werner reduces TTS truck growth view to down 2% to up 1% from up 1%-4% - Backs FY23 capex view of $350M-$400M
|
SYNA | Hot Stocks16:22 EDT Synaptics announces $500M increase to buyback program - Synaptics announced that its board has authorized a $500M increase in the company's existing share repurchase program, which expires in July 2025. The company has now cumulatively authorized the repurchase of up to $2.3B of common stock, of which approximately $977M remains available for repurchase.
|
MET | Hot Stocks16:19 EDT MetLife announces new $3B share repurchase authorization - MetLife announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock. The new authorization is incremental to the $202 million remaining under the company's prior authorization announced in May 2022. Commenting on the announcement, MetLife President and CEO Michel Khalaf said: "This new share repurchase authorization combined with the common stock dividend increase we announced in April reflects MetLife's financial strength and balanced approach to capital management. Taken together, these actions reinforce our commitment to being a sound capital steward for our shareholders."
|
OLED MKGAY | Hot Stocks16:10 EDT Universal Display acquires Merck KGaA's phosphorescent OLED emitter IP assets - Universal Display Corporation (OLED) announced that through its wholly-owned subsidiary UDC Ireland Limited, UDC has acquired the Phosphorescent OLED Emitter Intellectual Property assets of Merck KGaA (MKGAY). Representing more than 15 years of research and development, this portfolio has an average lifetime of 10 years and includes over 550 issued and pending patents around the world in 172 patent families. In addition, Universal Display Corporation and Merck KGaA, Darmstadt, Germany, entered into a new multi-year collaboration agreement that pertains to UDC's leading-edge green and yellow phosphorescent emitters and Merck KGaA, Darmstadt, Germany's state-of-the-art transport and host materials to create advanced PHOLED stacks. "We are pleased to complement and boost our vast global IP framework with Merck KGaA, Darmstadt, Germany's phosphorescent emitter patents and announce the extension and expansion of our OLED materials partnership," said Steven V. Abramson, President and Chief Executive Officer of Universal Display. "This strategic acquisition enhances our robust position in the OLED ecosystem. As the pioneer and leader in phosphorescent OLED technologies and materials, we are well situated to leverage Merck KGaA, Darmstadt, Germany's discoveries into our extensive research and intellectual property portfolios."
|
QCOM | Hot Stocks16:05 EDT Qualcomm down 4% following earnings, guidance - Qualcomm shares are down $4.78, or 4%, to $108.05 in after-hours trading.
|
ADBE | Hot Stocks15:49 EDT U.K.'s CMA launches inquiry into Adobe's acquisition of Figma - The U.K.'s CMA announced the launch of its inquiry into the acquisition of Figma by Adobe. The CMA said: "The Competition and Markets Authority is considering whether it is or may be the case that this transaction if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services." The deadline for the Phase 1 decision is June 30, the CMA said. Reference Link
|
KEY | Hot Stocks15:40 EDT KeyCorp raises prime lending rate to 8.25% from 8.00%, effective May 4
|
RDFN | Hot Stocks15:24 EDT Redfin announces launch of ChatGPT plugin - Redfin announced its launch of a ChatGPT plugin to "help people find homes that are a great fit for them." Users can join the waitlist to get access in the future, the company stated in a press release. "I think the most powerful way the Redfin ChatGPT plugin can make buying a home easier today is by suggesting homes and neighborhoods that would not have been uncovered via a map-based real estate search... We're just getting started, and the Redfin ChatGPT plugin is getting more powerful every day. We're excited to find new ways to use it to make buying, selling or renting a home simpler and more affordable," said Ariel Dos Santos, Redfin's vice president of product.
|
FITB | Hot Stocks14:44 EDT Fifth Third Bank to increase prime lending rate to 8.25% - Fifth Third Bank, National Association, announced it will increase its prime lending rate to 8.25%, effective immediately.
|
IMAX BABA | Hot Stocks14:01 EDT Imax grosses $7.8M during 6-day May Day holiday in China - Imax Corporation (IMAX) announced the company grossed $7.8M over the 6-day May Day holiday in China - the second highest grossing May Day period ever for Imax China. Driven by the strong performance of Alibaba's (BABA) "Born to Fly", Imax accounted for 16 out of the top 20 locations nationwide during one of the country's peak moviegoing periods. "The Chinese box office continues to make great strides in 2023, as the momentum of our record-breaking performance during Chinese New Year has carried across the year and into the Labor Day holiday," said Rich Gelfond, CEO of Imax. "With a very strong mix of Hollywood, local, and international blockbusters arriving in Chinese cinemas this summer, IMAX is set to strengthen its standing as the market leader in Chinese moviegoing and a powerful catalyst for the rebound of the country's box office."
|
MDXG | Hot Stocks13:54 EDT MiMedx shares spike 37% after reporting double-digit net sales growth in Q1 - Shares placental tissues firm MiMedx are up 37% or $1.40 per share to $5.21 in afternoon trading on Wednesday after reporting results earlier in the day that improved on the top and bottom lines. Joseph Capper, CEO, commented, "Our first quarter 2023 results demonstrate an excellent level of focus and execution across our organization, particularly among our commercial team. Our double-digit net sales growth this quarter was driven by robust demand for our new products in the surgical market and an accelerated growth rate in the private physician office setting. Our entire product offering is winning across the care settings we serve, as we work to make our best-in-class placental biologics products available to a large and growing number of patients each day."
|
CNI... | Hot Stocks13:40 EDT North American rail traffic down 4.6% for the week ending April 29 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending April 29. "Intermodal continues to suffer because of significantly lower trade activity at ports, weaker consumer demand, and continued excess retail inventories from the pandemic era," said AAR Senior Vice President John T. Gray. "These headwinds won't last forever. When they dissipate, railroads will be prepared to meet their customers' needs safely and reliably." Total U.S. weekly rail traffic was 481,960 carloads and intermodal units, down 4.9% compared with the same week last year. Total carloads for the week ending April 29 were 236,318 carloads, up 1.4% compared with the same week in 2022, while U.S. weekly intermodal volume was 245,642 containers and trailers, down 10.3% compared to 2022. Five of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included motor vehicles and parts, up 1,702 carloads, to 15,529; petroleum and petroleum products, up 1,349 carloads, to 10,177; and nonmetallic minerals, up 1,171 carloads, to 33,863. Commodity groups that posted decreases compared with the same week in 2022 included miscellaneous carloads, down 849 carloads, to 8,780; chemicals, down 670 carloads, to 33,864; and forest products, down 549 carloads, to 9,616. North American rail volume for the week ending April 29, on 12 reporting U.S., Canadian and Mexican railroads totaled 343,589 carloads, up 2.8% compared with the same week last year, and 326,666 intermodal units, down 11.4% compared with last year. Total combined weekly rail traffic in North America was 670,255 carloads and intermodal units, down 4.6%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link
|
IEP | Hot Stocks13:30 EDT Icahn Enterprises announces date change for Q1 earnings conference call - Icahn Enterprises L.P. announced that it has changed its earnings release date for the first quarter 2023 results on a conference call and webcast to Wednesday, May 10, 2023 at 10:00 a.m. Eastern Time. No reason was provided for the change.
|
META | Hot Stocks13:25 EDT Meta Platforms to 'vigorously fight' FTC's 'political stunt' - Andy Stone, head of Communications Director at Meta, tweeted a statement from the company on the FTC's "political stunt," stating that Meta "will vigorously fight this action and expect to prevail." Reference Link
|
BIIB | Hot Stocks13:22 EDT Biogen says EC extends Tecfidera regulatory market protection to February 2025 - In a regulatory filing, Biogen disclosed that on May 3, the European Commission notified the company of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025. Reference Link
|
AGEN GSK | Hot Stocks13:18 EDT Agenus up 4% after FDA approves GSK's Arexvy RSV vaccine - GSK's (GSK) older adult RSV vaccine candidate contains Agenus' (AGEN) QS-21 STIMULON.
|
GOOGL GOOG | Hot Stocks13:11 EDT Checks now 'a fully integrated Google product' - Alphabet's Google announce that "Checks is now a fully integrated Google product." "Checks is an AI-powered platform that helps companies with Google Play and iOS mobile apps quickly discover, communicate and fix privacy compliance issues. Checks is powered by Google's latest Large Language Models, or LLMs, and app understanding technologies, and provides automated analysis, end-to-end monitoring and relevant recommendations to help companies turn insights into action - all accessible through a single, intuitive dashboard," Fergus Hurley, Co-Founder & GM of Checks, and Nia Castelly, Co-Founder & Legal Lead of Checks, said in a Google blog post. Checks was initially launched in 2022 as a part of Google's in-house incubator. Reference Link
|
META | Hot Stocks13:05 EDT FTC proposes blanket prohibition preventing Facebook from monetizing youth data - The Federal Trade Commission proposed changes to the agency's 2020 privacy order with Facebook after alleging that the company has failed to fully comply with the order, misled parents about their ability to control with whom their children communicated through its Messenger Kids app, and misrepresented the access it provided some app developers to private user data. "Facebook has repeatedly violated its privacy promises," said Samuel Levine, Director of the FTC's Bureau of Consumer Protection. "The company's recklessness has put young users at risk, and Facebook needs to answer for its failures." As part of the proposed changes, Meta, which changed its name from Facebook in October 2021, would be prohibited from profiting from data it collects, including through its virtual reality products, from users under the age of 18. It would also be subject to other expanded limitations, including in its use of facial recognition technology, and required to provide additional protections for users. This is the third time the FTC has taken action against Facebook for allegedly failing to protect users' privacy, the FTC notes. The proposed changes to the 2020 order, which would apply to Facebook and Meta's other services such as Instagram, WhatsApp, and Oculus, include: Blanket prohibition against monetizing data of children and teens under 18; Pause on the launch of new products, services; Extension of compliance to merged companies; Limits on future uses of facial recognition technology; and Strengthening existing requirements. Reference Link
|
GSK | Hot Stocks13:03 EDT GSK reports FDA approves Arexvy RSV vaccine for older adults - GSK plc announced that the U.S. Food and Drug Administration has approved Arexvy for the prevention of lower respiratory tract disease caused by respiratory syncytial virus, or RSV, in individuals 60 years of age and older. "This is the first RSV vaccine for older adults to be approved anywhere in the world," GSK stated. Tony Wood, Chief Scientific Officer, GSK, said: "Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV vaccine for older adults, expanding GSK's industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries."
|
MULN | Hot Stocks12:54 EDT Mullen Automotive says 1-for-25 reverse stock split effective May 4 - Mullen Automotive announced that it will effect a 1-for-25 reverse stock split of its common stock that will become effective on May 4, at 12:01 a.m., Eastern Time. Mullen's Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "MULN" and will begin trading on a split-adjusted basis when the market opens on May 4. "The reverse stock split is primarily intended to bring the company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the company will meet the minimum bid price requirement," Mullen stated.
|
CPK | Hot Stocks12:47 EDT Chesapeake Utilities boosts quarterly dividend to 59c from 53.5c per share - Th board of Chesapeake Utilities voted to increase the quarterly cash dividend on the company's common stock from 53.5c per share to 59c per share. The action raises the 2023 annualized dividend by 22c from $2.14 to $2.36 per share, a 10.3% increase. The 59c per share dividend will be payable July 5, to all shareholders of record at the close of business on June 15. The company said, "Our diversified portfolio of underlying businesses, proven growth strategy, and strong financial position allows us to prudently allocate capital and maximize shareholder value. Looking forward, we remain well positioned to invest in our business and our people, capitalize on our growth strategy to achieve our earnings and capital expenditure targets, and consistently return capital to our shareholders. Our Board's decision to increase the annualized dividend rate to $2.36 per share marks our 20th consecutive year with increased dividends. At 10.3 percent, our five-year dividend growth nicely aligns with our five-year earnings growth. We remain focused on driving dividend growth supported by earnings growth to further long-term value creation for our shareholders."
|
TYL | Hot Stocks12:44 EDT Tyler Technologies CEO sells over 4,900 common shares - In a regulatory filing, Tyler Technologies president and CEO H. Lynn Moore disclosed the sale of 4,905.4097 common shares of the company on May 3 at a price of $379.4145 per share.
|
AMZN... | Hot Stocks12:37 EDT Epic Games' 'Fortnite' now available on Amazon Luna - Amazon (AMZN) and Epic Games announced that "Fortnite" will be available on Amazon's cloud gaming service, Amazon Luna, in the U.S., Canada, Germany, and the UK. Amazon Prime members can start playing the game Wednesday as part of their Prime membership, and all other customers can play with an existing Luna+ subscription or by signing up for a free seven-day trial of Luna+. "Fortnite has been the most requested game from Luna customers in the U.S. and we're thrilled to bring the title to the service," said Daniel Rausch, vice president, Amazon Entertainment Devices and Services. "We're committed to making gaming more accessible and more affordable, without the need for expensive hardware." Investors in Epic Games include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link
|
ATLX | Hot Stocks12:35 EDT Atlas Lithium Corp trading resumes
|
ATLX | Hot Stocks12:25 EDT Atlas Lithium Corp trading halted, volatility trading pause
|
MDRR | Hot Stocks12:03 EDT Medalist Diversified REIT announces effectiveness of 1-for-8 reverse stock split - Medalist Diversified REIT announced that the previously announced reverse stock split of shares of the Company's common stock, par value 1c per share, and a corresponding adjustment to the outstanding common units of its operating partnership, Medalist Diversified Holdings, at a ratio of 1-for-8 will become effective at 5:00 p.m. Eastern Time on May 3, 2023, and automatically convert every eight shares of Common Stock outstanding at that time into one share of Common Stock. The Common Stock will begin trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 4, 2023 under the ticker symbol "MDRR" with a new CUSIP number. The Reverse Stock Split will affect all holders of Common Stock uniformly and will not affect any common stockholder's percentage ownership interest in the Company, except for any fractional shares of Common Stock that would otherwise have resulted from the Reverse Stock Split which will be settled by cash payment, calculated on the basis of the closing trading price of the Common Stock on May 3, 2023 on Nasdaq multiplied by such fraction. Stockholders of record will receive information from VStock Transfer LLC, the Company's transfer agent, regarding their stock ownership and, if applicable, payments of cash in lieu of fractional shares. Stockholders who hold their shares in brokerage accounts or in "street name" are not required to take any action in connection with the Reverse Stock Split. As a result of the Reverse Stock Split, the number of shares of Common Stock outstanding will be reduced from 17,758,421 shares to approximately 2,219,000 shares as of the Effective Time. The Reverse Stock Split is intended to help the Company regain compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq. However, there can be no assurance that the Company will be able to regain compliance such requirement or maintain its listing on Nasdaq.
|
AVNS | Hot Stocks12:01 EDT Avanos falls -16.3% - Avanos is down -16.3%, or -$4.71 to $24.25.
|
EL | Hot Stocks12:01 EDT Estee Lauder falls -16.7% - Estee Lauder is down -16.7%, or -$40.94 to $204.28.
|
LEJU | Hot Stocks12:01 EDT Leju falls -28.5% - Leju is down -28.5%, or -$1.57 to $3.95.
|
HSC | Hot Stocks12:00 EDT Harsco rises 20.7% - Harsco is up 20.7%, or $1.39 to $8.08.
|
AHT | Hot Stocks12:00 EDT Ashford Hospitality rises 20.9% - Ashford Hospitality is up 20.9%, or 71c to $4.11.
|
UIS | Hot Stocks12:00 EDT Unisys rises 26.2% - Unisys is up 26.2%, or 89c to $4.26.
|
SPR... | Hot Stocks11:22 EDT Spirit AeroSystems now sees full year cash flow usage of $100M-$150M - On Spirit AeroSystems' Q1 earnings call, CFO Mark Suchinski stated: "Looking ahead, the rework and disruption from the Vertical FIN attach fitting issue as well as the risk of lower 737 deliveries will have a negative impact on free cash flow this year. The forward losses taken during the quarter will also result in additional pressure in our cash flows. Given these headwinds, we now expect our full year free cash flow usage to be in the range of $100M to $150M negative."
|
SPR | Hot Stocks11:20 EDT Spirit AeroSystems down 5% as Q1 earnings call continues - Shares of Spirit AeroSystems are down $1.61, or 5%, to $28.34 as the company continues to host a call with analysts following its Q1 earnings report.
|
SPR... | Hot Stocks11:16 EDT Spirit sees delivering fewer A320 ship sets this year than previously discussed - On Spirit AeroSystems' Q1 earnings call, CEO Thomas Gentile stated that execution within factories and mitigating supply chain challenges to meet the upcoming production rate increases across multiple programs remains "one of our major focus areas." Gentile added, according to a transcript: "We've made good progress in hiring and training new employees ahead of the planned 737 production rate increases later this year. We continue to expect ongoing supply chain challenges throughout the year, but do expect gradual improvement going into next year. In terms of expected deliveries on our other commercial programs this year, there is no change from what we discussed on our last earnings call of 40 to 45 ship sets on the 787 program and 60 ship sets on the A350 program. We continue to expect to deliver about 75 to 80, A220 units. For A320, we have received an updated production schedule from Airbus and now expected to deliver about 580 ship sets this year, about 85 fewer than we previously discussed last quarter."
|
GLBZ | Hot Stocks11:13 EDT Glen Burnie trading resumes
|
SPR BA | Hot Stocks11:08 EDT Spirit AeroSystems sees $31M hit to full-year gross profit from 737 issue - In earnings presentation slides, Spirit AeroSystems (SPR) commented on notified Boeing (BA) of a quality issue on the vertical fin attach fittings of certain models of the 737 fuselage and having supported Boeing and the FAA for "their confirmation that it was not an immediate safety of flight issue." Based on preliminary financial assessment, disruptions and rework within Spirit's factory is expected to have a negative impact of $31M to full-year gross profit, of which $17M is reflected in Q1 financial results, the company stated. The rework cost on available units in Wichita is expected to average $100K-$150K per unit, approximately $5M in total, though "additional costs are expected but cannot be reasonably estimated at this time," the company stated in its slides. Spirit adds that it revised its assembly process and "have started to build and deliver new conforming fuselages," while implementing "additional protocols to reinforce our quality systems to prevent similar occurrences in the future."
|
GLBZ | Hot Stocks10:56 EDT Glen Burnie trading halted, volatility trading pause
|
UP | Hot Stocks10:45 EDT Wheels Up appoints David Godsman CDO, Kristen Lauria as CCMO - Wheels Up Experience announced two key additions to its senior management team to amplify its customer-focused business strategies and deliver on its profitability objectives. David Godsman will join as Wheels Up's first Chief Digital Officer to lead the company's digital transformation and technology initiatives. In addition, Kristen Lauria will join as the company's new Chief Customer and Marketing Officer to focus on Wheels Up's member value proposition and customer acquisition. Godsman joins from Foro where he served as CEO and Director. At Wheels Up, Godsman will oversee the company's Digital Product, Technology and Data Services teams and focus on leveraging its technology investments and infrastructure to drive business results, further improve operations and deliver an extraordinary member experience. Lauria succeeds Lee Applbaum who is departing Wheels Up to focus on personal and entrepreneurial ventures. She steps into an expanded role that includes overseeing the company's brand, creative and customer acquisition and retention, as well as a special focus on the member and customer experience. She is already well versed in the business, having worked with the company as a management consultant since January 2023. Godsman will officially join on June 1 and will be based in Charlotte, N.C. Lauria will join on May 15 and will be based in New York.
|
XELA | Hot Stocks10:21 EDT Exela Technologies urges stockholders to vote for reverse stock split amendment - The company said, "Exela Technologies is reminding our shareholders to vote TODAY FOR Proposal 1, an amendment to effect a reverse stock split. Why? Exela is better served by all of our constituents to remain on Nasdaq for continuity. Due to our broad and global investor global base, it is critical that stockholders vote, no matter how many shares they own."
|
GIC | Hot Stocks10:00 EDT Global Industrial falls -17.7% - Global Industrial is down -17.7%, or -$4.67 to $21.64.
|
EL | Hot Stocks10:00 EDT Estee Lauder falls -20.6% - Estee Lauder is down -20.6%, or -$50.40 to $194.82.
|
LEJU | Hot Stocks10:00 EDT Leju falls -21.4% - Leju is down -21.4%, or -$1.18 to $4.34.
|
CWH | Hot Stocks10:00 EDT Camping World rises 11.8% - Camping World is up 11.8%, or $2.57 to $24.39.
|
HSC | Hot Stocks10:00 EDT Harsco rises 19.6% - Harsco is up 19.6%, or $1.31 to $8.00.
|
UIS | Hot Stocks10:00 EDT Unisys rises 21.3% - Unisys is up 21.3%, or 72c to $4.10.
|
UBER LYFT | Hot Stocks09:59 EDT Stripe announces expanded partnership with Uber - Stripe announced an expanded global partnership with Uber Technologies (UBER). Uber will expand its use of Stripe's payments platform, including in the U.S., "to reduce costs and give customers more flexible ways to pay for Uber Rides and Uber Eats," Stripe said in a statement. Uber will use Link and Stripe Financial Connections to allow customers to add bank accounts without leaving the Uber app. TechCrunch pointed out that Stripe has been a longtime partner of Uber competitor Lyft (LYFT). Lyft will remain a customer of Stripe's, Stripe president Will Gaybrick confirmed to TechCrunch. Reference Link
|
BAOS | Hot Stocks09:58 EDT Baosheng Media Group Holdings Ltd trading resumes
|
ASNS | Hot Stocks09:51 EDT Actelis Networks Inc trading resumes
|
BGXX | Hot Stocks09:50 EDT Bright Green Corp trading resumes
|
BAOS | Hot Stocks09:48 EDT Baosheng Media Group Holdings Ltd trading halted, volatility trading pause
|
GIC | Hot Stocks09:47 EDT Global Industrial falls -11.7% - Global Industrial is down -11.7%, or -$3.09 to $23.22.
|
EL | Hot Stocks09:47 EDT Estee Lauder falls -19.1% - Estee Lauder is down -19.1%, or -$46.87 to $198.35.
|
LEJU | Hot Stocks09:47 EDT Leju falls -32.1% - Leju is down -32.1%, or -$1.77 to $3.75.
|
BLDR | Hot Stocks09:47 EDT Builders FirstSource rises 8.8% - Builders FirstSource is up 8.8%, or $8.40 to $103.61.
|
UIS | Hot Stocks09:47 EDT Unisys rises 9.5% - Unisys is up 9.5%, or 32c to $3.70.
|
LTHM | Hot Stocks09:47 EDT Livent rises 11.9% - Livent is up 11.9%, or $2.51 to $23.53.
|
ASNS | Hot Stocks09:46 EDT Actelis Networks Inc trading halted, volatility trading pause
|
VCIG | Hot Stocks09:44 EDT VCI Global Ltd trading resumes
|
LEJU | Hot Stocks09:43 EDT Leju trading resumes
|
ALTI | Hot Stocks09:41 EDT AlTi Global, Inc trading resumes
|
MRCY | Hot Stocks09:40 EDT Mercury Systems trading resumes
|
JXJT | Hot Stocks09:40 EDT JX Luxventure Ltd trading resumes
|
ENTX | Hot Stocks09:40 EDT Entera Bio announces publication of GLP-2 preclinical data - Entera Bio announced that its pre-clinical manuscript entitled "Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog, Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome" has been accepted for publication by the International Journal of Peptide Research and Therapeutics. Short bowel syndrome is a rare and potentially life-threatening malabsorptive condition caused by a significant loss of functional bowel mass or physical bowel mass. SBS patients have a reduced ability to absorb nutrients and fluids and are at risk of malnutrition, unintended weight loss and additional symptoms due to the loss of essential vitamins and minerals. SBS is the most common cause of chronic intestinal failure, accounting for approximately 75% of cases of chronic intestinal failure in adults and 50% such events in children. Teduglutide, a GLP-2 analog and mainstay treatment for SBS, is known to enhance intestinal absorption. Teduglutide treatment requires daily sub-cutaneous injections. "There are several new generation GLP-2 analogs under development which may also require chronic injections. As part of our R&D initiatives, Entera is leveraging on its proprietary platform to enable a potential first-in-class oral GLP-2, daily tablet treatment for patients with short bowel syndrome and other disorders requiring parenteral nutrition. We are looking forward to sharing our in vivo findings with the community in the coming weeks," said Miranda Toledano, CEO.
|
KTCC | Hot Stocks09:38 EDT KeyTronicEMS trading resumes
|
SES | Hot Stocks09:38 EDT SES AI offers clarification on recent sale of shares by management - SES recently celebrated its 11-year anniversary and its 1-year anniversary since listing on the New York Stock Exchange. As a result, a portion of restricted stock units that were granted to management shortly after listing recently vested, creating a tax liability for some officers of the company. After the market closed on May 2, several members of SES management filed Form 4s, which are a statement of change in beneficial ownership in SES, including CEO Qichao Hu. The transactions reported on these Form 4s were carried-out pursuant to an automatic "sell-to-cover" instruction for the applicable withholding taxes on the vested RSUs. Proceeds from the share sales were collected by SES for the sole purpose of covering the aforementioned tax liabilities. "I have no intention to sell shares in SES and have never sold a single share in SES aside for paying taxes due on vesting RSUs. We continue to make incredible progress on our Li-Metal battery cells and I look forward to providing an update on our business when we report our first quarter earnings after market close on May 8", said Founder and CEO Qichao Hu.
|
PACW | Hot Stocks09:37 EDT PacWest Bancorp trading resumes
|
LEJU | Hot Stocks09:37 EDT Leju trading halted, volatility trading pause
|
ALTI | Hot Stocks09:36 EDT AlTi Global, Inc trading halted, volatility trading pause
|
MRCY | Hot Stocks09:35 EDT Mercury Systems trading halted, volatility trading pause
|
SPHR | Hot Stocks09:35 EDT Sphere Entertainment completes sale of interest in Tao Group Hospitality - Sphere Entertainment has completed the sale of its 66.9% majority interest in Tao Group Hospitality to Mohari Hospitality, a global investment company focused on the luxury lifestyle and hospitality sectors. The completion of the sale follows a successful bidding process with multiple parties, which reflects that since the Company acquired a majority interest in 2017, Tao Group Hospitality has transformed into a global powerhouse in entertainment dining and hospitality. As previously disclosed, in connection with the sale, Sphere Entertainment has also entered into a multi-year agreement with Tao Group Hospitality for ongoing consulting, marketing, and support services.
|
HHS | Hot Stocks09:35 EDT Harte Hanks Inc trading resumes
|
JXJT | Hot Stocks09:35 EDT JX Luxventure Ltd trading halted, volatility trading pause
|
VCIG | Hot Stocks09:34 EDT VCI Global Ltd trading halted, volatility trading pause
|
KTCC | Hot Stocks09:33 EDT KeyTronicEMS trading halted, volatility trading pause
|
PACW | Hot Stocks09:32 EDT PacWest Bancorp trading halted, volatility trading pause
|
HHS | Hot Stocks09:30 EDT Harte Hanks Inc trading halted, volatility trading pause
|
BGXX | Hot Stocks09:21 EDT Bright Green launches EB-5 website, program - Bright Green confirmed the launch of their EB-5 website and committed program following their recent historic U.S. Drug Enforcement Administration approval and registration. The Company announced in February that it has commenced utilization of the U.S. Citizenship and Immigration Services' EB-5 Program to accelerate its 2023 growth strategy and generate significant capital for use in its greenhouse construction and operations in Grants, New Mexico. The DEA registration followed the completion of a significant process, which culminated with the agency's site visits and inspections of Bright Green's agricultural complex in Grants, New Mexico, with the final inspection on March 22, 2023.
|
F | Hot Stocks09:20 EDT Ford reports April U.S. sales up 4% y/y to 184,002 vehicles - Total SUV sales were down 11.3% to 82,367, while total truck sales were up 21% to 96,493 vehicles and car sales were up 17.2% y/y to 5,142 vehicles.
|
AVTX | Hot Stocks09:18 EDT Avalo Therapeutics welcomes Walter Pardo, Wealth Financial Partners team - Avantax welcomes Walter "Wally" Pardo and his New Jersey-based Wealth Financial Partners LLC team. Pardo is looking to Avantax for new growth opportunities, including the ability to expand services and investment expertise with the support of Avantax's Home Office specialists, as part of Pardo's commitment to the marriage of tax and financial planning.
|
GANX | Hot Stocks09:17 EDT Gain Therapeutics awarded CHF 2.5M Innosuisse grant - Gain Therapeutics announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million to develop GT-02287, Gain's lead program for GBA1 Parkinson's disease. The Company's Swiss Accelerator innovation project supported by Innosuisse entitled "Harnessing Structurally Targeted Allosteric Regulators to treat Parkinson's Disease" includes clinical pharmacology and preclinical studies with the Company's drug candidate GT-02287, which will be conducted as the lead program progresses through Phase 1 and Phase 2 clinical studies in GBA1 Parkinson's disease. GBA1mutations are the major genetic risk factor for Parkinson's disease and are associated with earlier onset of the disease, faster disease progression and increased rates of cognitive decline. Mutations of the GBA1 gene cause misfolding and dysfunction of the enzyme beta-glucocerebrosidase. Preclinical models of GT-02287 have shown the ability of this orally bioavailable and brain-penetrant molecule to target and bind to GCase, prevent its degradation and allow its transport to the lysosomes where the enzyme can carry out its biological function. Furthermore, the data from preclinical models demonstrate that enhancement of lysosomal GCase activity by GT-02287 protects against key pathological features of Parkinson's disease, including alpha-synuclein related pathology and an increase in the survival of dopaminergic neurons. These findings support the potential of GT-02287 to slow or halt disease progression in GBA1 Parkinson's disease.
|
CYCC | Hot Stocks09:16 EDT Cyclacel Pharmaceuticals receives $4.7M R&D tax credit - Cyclacel Pharmaceuticals announced that it received a payment of GBP 3.9M as a research & development tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represents the amount disclosed in the company's audited financial statements at December 31, 2022.
|
BGXX | Hot Stocks09:15 EDT Bright Green Corp trading halted, news pending
|
EXEL | Hot Stocks09:14 EDT Farallon nominates three independent directors to Exelixis board - Funds managed by Farallon Capital Management own approximately 7.2% of the outstanding shares of Exelixis, making it the Company's largest active shareholder. Today, Farallon filed definitive proxy materials in connection with Exelixis' 2023 Annual Meeting of Shareholders which has been scheduled for May 31. Farallon also sent a letter today to the Company's shareholders outlining why change is urgently needed in Exelixis' boardroom and why shareholders should support Farallon's three independent director nominees for election to the Board of Directors at the upcoming Annual Meeting. Farallon Capital Partners together with certain of its affiliates, has owned Exelixis stock continuously since 2018. We currently own approximately 7.2% of the outstanding shares of Exelixis making us the Company's largest active shareholder. Farallon is a fundamental value investor that takes great pride in building strong, lasting relationships with boards and management teams. Our preference is to work constructively with our portfolio companies to help drive sustainable value and growth. Only in situations where it is absolutely necessary do we publicly criticize or challenge a Board's stewardship. This is one of those situations. As a result, we have nominated three candidates to the Board of Directors at this year's May 31 Annual Meeting of Shareholders.
|
FGH | Hot Stocks09:10 EDT FG Group says STS selected as exclusive technical support partner to Bow Tie - FG Group Holdings announced that Strong Technical Services has been selected by Bow Tie Management as its exclusive technical support partner. In this capacity, STS will support Bow Tie's locations across the United States by providing installation, on-site servicing, and audio solutions.
|
CLSK | Hot Stocks09:10 EDT CleanSpark mined 524 bitcoin in April - CleanSpark released its unaudited bitcoin mining and operations update for the month ending April 30, 2023. "Our high efficiency measures and low power rates have made meaningful contributions to our margins this month even as difficulty has substantially increased," said Zach Bradford, CEO. "The result of these efforts is that while we have mined fewer bitcoin this month, the bitcoin we have mined is being driven to our bottom line. As we look to the next few months, we expect Washington to be fully energized, which will bump our hashrate as we maintain our competitive edge in these tight market conditions. We are looking forward to sharing our quarterly performance in more detail, including some exciting updates on our expansion plans in Washington and Sandersville, on our earnings call next week. We hope shareholders and other stakeholders will tune in." April Bitcoin Mining Update, unaudited: Bitcoin mined in April: 524; CY2023 bitcoin mined: 2,395; Total BTC holdings as of April 30: 313; Total BTC converted for operations and growth in April: 407; Currently deployed fleet of about 67,700 latest-generation bitcoin miners with a hashrate of 6.7 EH/s
|
SGA | Hot Stocks09:08 EDT Saga Communications sees 2023 capex $5M-$5.5M - The Company's balance sheet reflects $37.5 million in cash and short-term investments as of March 31, 2023 and $35.0 million as of May 1, 2023. The Company expects to spend approximately $5.0 - $5.5 million for capital expenditures during 2023.
|
CCLD | Hot Stocks09:08 EDT CareCloud announces new partnership with Phoenix Family Medical Clinic - CareCloud announced a new partnership with Phoenix Family Medical Clinic that will offer technology-enabled revenue cycle management services and an integrated electronic health record solution, chronic care management, and remote patient monitoring to the Arizona-based clinic. "We chose CareCloud because we needed a modern, cloud-based EHR and patient scheduling software that would enable us to provide better patient care while also improving our billing processes," said Shallu Vaid, practice administrator at Phoenix Family Medical Center. "CareCloud's comprehensive scheduling system, e-prescribing, a patient portal, and lab integration are designed to make it easier for us to manage patient care and billing, while also improving the patient experience. With CareCloud, we have a partner we can trust to help us deliver high-quality care to our patients and thrive as a healthcare practice."
|
VLD | Hot Stocks09:07 EDT Velo3D announces strategic partnership with PhysicsX for AI simulation tooling - Velo3D announced a strategic partnership with PhysicsX through Velo3D's Technical Partner Program. The partnership gives Velo3D customers access to PhysicsX's artificial intelligence AI -enabled physics simulation workflows to hyper-accelerate simulation loops, improve simulation fidelity, and algorithmically explore complex design spaces to unlock new performance levels. It also provides PhysicsX customers with access to the most advanced metal additive manufacturing capabilities available on the market today, so they can produce novel, highly optimized part designs with ease. "We started working with PhysicsX when we were building the Sapphire XC printer because we needed to optimize the flow of gas in the printer build chamber to eliminate soot build-up around the laser windows of the system," said Benny Buller, Velo3D Founder and CEO. "We quickly realized that PhysicsX's capabilities could be a big boon to many of our customers who are pushing design performance limits. After working closely with them over the past two years, we've formalized our partnership to expose customers to the engineering synergy that exists by combining both companies' technologies."
|
ALGT | Hot Stocks09:07 EDT Allegiant raises FY23 EPS view for airline only to $9.00-$13.00 from $5.00-$9.00 - Lowers FY23 System ASMs y/y change view to 0%-3% from 2%-6%. Reaffirms FY23 available seat miles/gallon view ~84; depreciation expense view $230M-$240M; and interest expense view and $150M-$160M.
|
TMP | Hot Stocks09:06 EDT Tompkins Financial CFO, COO Francis Fetsko to retire - The board of directors of Tompkins Financial announced that Francis Fetsko has communicated his plans to retire as chief financial officer and chief operating officer of Tompkins Financial Corp. in the fall of 2023, after twenty-seven years of service to the company. While Fetsko will step back from his current role in the fall, he has agreed to remain with the company in a part-time capacity, as director of strategy development, through the end of 2024. The company will undertake a succession planning process to identify the best candidate to fill Fetsko's role upon his retirement, which may include both internal and external candidates.
|
RIOT | Hot Stocks09:06 EDT Riot Platforms produced 639 BTC in April, up 26% from last year - Riot Platforms announces unaudited production and operations updates for April 2023. Riot produced 639 BTC, an increase of approximately 26% as compared to April 2022 production of 508 BTC. Riot held approximately 7,112 BTC as of April 30, 2023, all produced by the Company's self-mining operations. Riot sold 600 BTC, generating net proceeds of approximately $17.6 million. Riot had a deployed fleet of 94,176 miners, with a hash rate capacity of 10.5 exahash per second, as of April 30, 2023, which excludes 17,040 miners that are offline as a result of damage to Building G from the severe winter weather in late December in Texas. "Riot produced 639 Bitcoin in the month of April, continuing our strong monthly mining results in 2023 amidst a competitive Bitcoin mining environment, thanks to the dedication and hard work of our teams," said Jason Les, CEO of Riot. "Additionally, as we near completion of the long-term expansion project at our Rockdale Facility, our teams have been focused on operational enhancements to increase efficiency, including improving cooling in Buildings D and E through the installation of waterwalls. We also continue to work on repairs to our damaged immersion building, Building G, which remains on track to come back online in the second half of 2023.
|
LPLA | Hot Stocks09:05 EDT LPL Financial: Nate Carlon joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Nate Carlon of Carlon Wealth Advisors has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $300 million in advisory, brokerage and retirement plan assets, and joins LPL from Stifel Financial.
|
MBOT | Hot Stocks09:03 EDT Microbot Medical's LIBERTY Robotic System surpasses 100th catheterization - Microbot Medical announced the system has surpassed its 100th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets, such as distal branches of hepatic, gastric, splenic, mesenteric, renal, hypogastric arteries. Moreover, all of the procedures were completed without notable signs of intraoperative injury. The LIBERTY Robotic System performed safely, consistently and reliably, regardless of the operator. "The results of over 100 catheterizations represent an incredible accomplishment and further strengthen the LIBERTY Robotic System's previous collected data," commented Harel Gadot, Chairman, CEO and President. "The multiple studies have allowed us to demonstrate the system's consistent performance and safety profile, reaching the pre-determined vascular target. We believe that the data and feedback we have amassed and will continue to collect during additional studies scheduled in the U.S., will facilitate and support our regulatory pathway with the US Food and Drug Administration, including our plan to submit Investigational Device Exemption in the coming months."
|
VZ | Hot Stocks09:03 EDT Verizon brings private wireless network solutions to Miami Grand Prix - Verizon is bringing private wireless network solutions to this year's Formula 1 Crypto.com Miami Grand Prix. The company deployed a Private Managed Wireless Solution at the track that enables venue management solutions including ticket scanning, digital sign management, multiple point of sale terminals for various merchants, and immediate uploads for photographers looking to cover the action as it unfolds. With nearly a quarter of a million people expected to attend the three-day event, a dedicated private network delivers high-speed, high-capacity, and low-latency for these applications as well as reduced interference and greater privacy and security.
|
YUM | Hot Stocks09:03 EDT Yum! Brands sees FY23 development similar to FY22, FY21 - Says starting in Q2 Russia business will no longer be reported in results. Says returning to more normalized operating environment. Says FY23 development will be similar to FY22 and FY21. Says has real confidence to deliver net new unit growth. Comments taken from Q1 earnings conference call.
|
CVS | Hot Stocks09:03 EDT CVS Health says ability to generate cash 'outstanding' - Says liquidity, capital position "remain excellent." Expects 2H23 earnings to represent slightly more than 50% of FY total. Expects Q3 earnings "slightly higher" than Q4. Sees FY23 CapEx $2.8B-$3B.
|
BRQS | Hot Stocks09:03 EDT Borqs requests for hearing regarding the $1 minimum bid price deficiency - Borqs Technologies announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that the Company has not regained compliance with the minimum bid price of $1 required for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Company has engaged the firm of Donohoe Advisory Associates LLC to request a hearing which will stay the suspension or delisting action pending the hearing and the expiration of any extension period granted by the Panel following the hearing. Consequently, the Company's ordinary shares are expected to remain listed on The Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel will determine to continue the Company's listing on The Nasdaq Capital Market or that the Company will timely evidence compliance with the terms of any extension that may be granted by the Panel following the hearing.
|
NCNO | Hot Stocks09:02 EDT nCino partners with Grasshopper for multiple nCino solutions - nCino announces its partnership with Grasshopper, the client-first digital bank built for the business and innovation economy. Grasshopper will leverage multiple nCino solutions, including Portfolio Analytics, Commercial Banking and Customer Engagement, to enhance portfolio management and reporting, speed to market for loan closing, and line of sight into the loan process across its lending divisions - which support venture and private equity funds, commercial real estate and SBA borrowers.
|
BEAT | Hot Stocks08:56 EDT HeartBeam sees 'no meaningful FY23 commercial revenue' amid strategic focus - HeartBeam has adjusted its strategic focus to enable timely delivery of its breakthrough ambulatory VECG products, the Company's key future value drivers, as follows: Immediately focus on obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo credit card- sized VECG device, followed by a second 510(k) clearance on the system's ability to synthesize an electrocardiogram . The goal of this second FDA clearance is to demonstrate that HeartBeam's synthesized 12-lead ECG is equivalent to standard recorded 12-lead ECGs. These clearances provide a key value creation path, as they will enable physicians to remotely monitor patients and immediately interpret any concerning cardiac events. Demonstrate through clinical trials in 2023 the performance of the HeartBeam AIMIGo platform, which we believe is the most advanced ambulatory cardiac detection platform available. HeartBeam believes this will drive clinical and patient adoption. Shift the commercial launch until obtaining the 510(k) clearance for 12-lead equivalence. The company plans to submit this application to the FDA in late 2023 and pursue initial commercialization in 2024. Undertake an aggressive pre-commercial effort to define initial market segments and identify potential business partners. Continue aggressive development of its intellectual property through our partnership with PatentVest, a unified technology development and patent law firm focused on creating IP leadership for development stage technology companies. The partnership is clearly focused on the goal of creating clear leadership in the area of ambulatoryVECG cardiac detection. Add world leading Key Opinion Leaders to our Medical Advisory Board to help guide our clinical and regulatory development. These Advisory Board members will be announced in thenear future. As a result of these strategic goals, we are updating our financial guidance and expect no material commercial revenue for 2023.
|
BEAT | Hot Stocks08:51 EDT HeartBeam completes $25M capital raise and updates FY23 strategic focus - HeartBeam announced closing of its secondary offering of 16,666,666 shares of HeartBeam's common stock. This financing will allow HeartBeam to fund its upcoming clinical and regulatory milestones related to its HeartBeam AIMIGo system and prepare for commercialization in 2024. HeartBeam received net proceeds of $23.2M from the offering, after deducting the placement agent discounts and commissions and offering expenses. HeartBeam has adjusted its strategic focus to enable timely delivery of its breakthrough ambulatory VECG products, the Company's key future value drivers, as follows: immediately focus on obtaining an FDA 510 clearance for the HeartBeam AIMIGo credit card- sized VECG device, followed by a second 510k clearance on the system's ability to synthesize an electrocardiogram. . . Shift the commercial launch until obtaining the 510(k) clearance for 12-lead equivalence. The company plans to submit this application to the FDA in late 2023 and pursue initial commercialization in 2024. Undertake an aggressive pre-commercial effort to define initial market segments and identify potential business partners. .."We are extremely pleased to have received this additional funding, which will allow us to achieve our important upcoming milestones and extends our cash runway into late 2024," said Branislav Vajdic, Ph.D. HeartBeam Founder and CEO. "We are also excited to be working with Public Ventures, which is an outstanding strategic partner with a long track record of helping companies grow and realize their full potential. The strategic focus we are announcing today are important steps for us to demonstrate the value of our novel VECG technology and to achieve the clinical and regulatory milestones to bring these important products into the hands of physicians and patients."
|
CNSP | Hot Stocks08:49 EDT CNS Pharmaceuticals investigating potential naked short selling - CNS Pharmaceuticals is investigating potential naked short selling of its stock and has retained well-known analytics firm, Shareholder Intelligence Services, to review the trading patterns of the Company's common stock. The Company values its shareholders and wants to have all available data at its disposal to act in its fiduciary capacity.
|
KPTI | Hot Stocks08:49 EDT Karyopharm repots interim data from open-label Phase 1/2 study of eltanexor - Karyopharm Therapeutics announced interim data from the Phase 2 portion of the open-label Phase 1/2 study of single-agent eltanexor in patients with higher R/R myelodysplastic neoplasms. The data, featured in a poster presentation at the 17th International Congress on Myelodysplastic Syndromes, showed that eltanexor has promising single-agent efficacy with a generally manageable safety profile. As of the February 8, 2023 data cut-off date, 30 patients had been treated with 10mg eltanexor, oral, on Days 1-5 of each week. Eltanexor demonstrated a 27% overall response rate, or ORR, in the intent-to-treat, or ITT, population and a 31% ORR in the efficacy evaluable population. Median overall survival (mOS) was 8.7 months in both populations. Transfusion independence rate for red blood cells and/or platelets was 29%. Eltanexor was generally well-tolerated and manageable. The most common adverse events were asthenia, 47%; diarrhea, 43%; and nausea, 33%, the majority of which were Grade 1-2. The most common Grade greater than or equal to3 treatment-emergent AEs were neutropenia, thrombocytopenia, and asthenia.
|
XBIO | Hot Stocks08:43 EDT Xenetic engages Scott Cullison as executive consultant for business development - Xenetic Biosciences has engaged Scott Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Cullison currently serves as the Owner/Consultant for Stride BDCOM Consulting.
|
VSAC | Hot Stocks08:42 EDT Newsight Imaging, Brightlaser awarded collaboration grant - Newsight Imaging and Brightlaser Limited, a global competitive supplier in VCSEL, vertical-cavity surface-emitting laser, technologies, announced that Brightlaser has been awarded the first grant from the Hong Kong-Israel R&D Cooperation Programme to develop a next generation 3D home and industrial security LiDAR camera solution. "We are privileged to be working with Brightlaser on this collaboration, and we see strong synergies between our companies and technology to develop an innovative new solution for home and industrial security," said Eli Assoolin, Co-Founder and CEO of Newsight. "Our joint solution is based on solid-state LiDAR without any moving parts, an eTOF 3D CMOS sensor system and specific adjusted optics for illumination and imaging. We will work to design the receiving and the image processing systems using our eTOF proprietary patented technology, and Brightlaser will design the light transmitter sub-system. We thank the ITC and the IIA for their support and funding and look forward to working with Brightlaser over the next 18 months to develop our joint solution." On August 30, 2022, Newsight Imaging announced that it has entered into a definitive agreement to become publicly listed through a merger transaction with Vision Sensing Acquisition.
|
VEV | Hot Stocks08:42 EDT Vicinity Motor secures $9M credit facility with Export Development Canada - Vicinity Motor has secured a new $9M credit facility from Export Development Canada to fund working capital and capital expenditures as the Company begins production of the VMC 1200 at its facility in Ferndale, Washington. The New Credit Facility, which is designed for capital expenditures and working capital needs, bears interest at a rate of prime plus a per annum margin between 375 and 500 basis points depending on the Company's full year EBITDA, and is secured by the existing assets of the Company. This New Credit Facility complements the previously announced $30M credit facility, which is required to be used for VMC 1200 production costs, excluding labor and overhead.
|
SYTA | Hot Stocks08:41 EDT Siyata Mobile receives over $900,000 order for SD7 handsets - Siyata Mobile has received a purchase order for over $900,000 to supply a U.S. public school district with its mission-critical PoC SD7 handsets and accessories.
|
SRGA | Hot Stocks08:40 EDT Surgalign to collaborate with Vaccaro, Nunley to advance HOLO AI insights - Surgalign announces new collaborative alliances with Dr. Pierce Nunley and the Spine Institute of Louisiana, and Dr. Alexander Vaccaro, an advisor to Surgalign. These new collaborations seek to advance Surgalign's recently introduced HOLO AI Insights solution for lumbar spine imaging, which was launched in March 2023, and build upon the previous collaboration with Spine Institute of San Diego. All of the parties involved are focused on using HOLO AI Insights with a goal to enhance clinical decision support and patient care through the use of artificial intelligence. Dr. Vaccaro has served as President of Rothman Orthopaedics since 2014 and is the Richard H. Rothman Professor and Chairman in the Department of Neurosurgery at Thomas Jefferson University in Philadelphia, PA. Dr. Nunley, who will be leading efforts for Spine Institute of Louisiana, is an experienced clinical research Principal Investigator for over 20 years. Terry Rich, President and Chief Executive Officer of Surgalign added, "Gaining surgeon feedback is paramount to the continuous advancement of our AI technology and with Dr. Vaccaro, Dr. Nunley, and the team at San Diego Spine Foundation, we have aligned with some of the best spine surgeons in the world. We look forward to working with them to gain their insights and enhance our AI capabilities to drive further adoption in the market and improve patient care."
|
VERU | Hot Stocks08:39 EDT Veru enters common stock purchase agreement with Lincoln Park Capital - Veru has entered into a common stock purchase agreement for the purchase of up to $100 million with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the Agreement, LPC has committed to purchase up to $100 million of Veru's common stock at Veru's sole discretion from time to time over a 36-month period. Veru controls the timing and amount of any future sales of its shares and LPC is obligated to make purchases in accordance with the terms of the Agreement, subject to various limitations contained in the Agreement, including those under the Nasdaq listing rules.
|
SMMT | Hot Stocks08:39 EDT Summit Therapeutics announces initial indications for clinical trials for SMT112 - Summit Therapeutics announced that it has determined its first two indications in non-small cell lung cancer NSCLC in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab. Summit has held multiple meetings with the US Food and Drug Administration during the first quarter of 2023 regarding its planned Phase III clinical program and incorporated this feedback accordingly. We plan to initiate clinical studies in the following indications: Ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor EGFR -mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor ..."I am immensely proud of the speed and efficiency of our team to enable clinical trials for SMT112," stated Robert W. Duggan, Chairman & Chief Executive Officer of Summit. "I am particularly enthusiastic about the potential of ivonescimab: this shared enthusiasm is the impetus behind Team Summit's rapid development to enter into multiple Phase III clinical trials with SMT112. With our confidence in our ability to clinically develop, achieve regulatory approvals, and effectively commercialize a quality product, we believe that we have the opportunity to make a significant difference in the lives of those patients who could benefit from this innovative therapy." "Our agreement to in-license ivonescimab from our high-achieving partner, Akeso, went effective this past January," added Dr. Maky Zanganeh, Co-CEO & President of Summit. "In just over three months' time, we are preparing to enroll patients in our first Phase III clinical trial, while actively preparing to launch our second Phase III study later this year. The commitment, preparation, diligence, and vision of Team Summit is shining brightly today and reflects the work we have completed to maximize the opportunities for the success of ivonescimab." Ivonescimab is an investigational product and is not approved for use by any health authority. Its efficacy and safety for the treatment of any indication have not been established.
|
PRPH | Hot Stocks08:38 EDT ProPhase Labs provides update on progress, development for LB-1 - ProPhase Labs provided an update regarding its progress and development strategy for Linebacker-1, LB-1. Linebacker is a small molecule, multi-kinase inhibitor that is being developed by the Company's wholly owned subsidiary, ProPhase BioPharma, as a potential mono-therapy and co-therapy option for hard-to-treat cancers. Originally viewed as a co-therapy, the pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy. In Q1 of 2023, ProPhase collaborated with Eurofins, a globally recognized leading drug discovery company, to execute an in-depth analysis of Linebacker-1 to determine how many cancer-relevant kinases were affected by Linebacker-1 out of a possible 468 enzymes. Importantly, the Eurofins analysis revealed several unique targets affected by Linebacker-1 that cancer research organizations highlight as critically important. In line with these impressive results, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers. As development continues, ProPhase intend to position Linebacker-1 as a potential new option for cancer patients suffering from a current lack of quality treatment options. The company intends to focus a majority of 2023 on developing a more in-depth understanding of the unique pathways ProPhase believes Linebacker may impact, as well as taking the necessary steps to meet the requirements for an IND submission to the FDA including: Cross-over analysis and machine learning to elucidate most affected signaling pathways; Maximum Tolerated Dose studies and safety confirmations; Opportunities for synergies with existing, but underwhelming, commercial medicines; Optimization of treatable neoplastic conditions within unsaturated areas
|
INZY | Hot Stocks08:38 EDT Inozyme reports inducement grants under Nasdaq listing rule - Inozyme Pharma announced that the Company granted stock options to new employees to purchase shares of the Company's common stock, pursuant to the Company's 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Company's compensation committee granted nonstatutory stock options to purchase up to an aggregate of 170,000 shares of the Company's common stock to four new employees on May 1, 2023, at an exercise price of $5.81 per share, the closing price per share of the Company's common stock as reported by Nasdaq on May 1, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's start date and 2.0833% of the shares underlying the option vesting monthly thereafter, subject to such employee's continued service to the Company through the applicable vesting dates.
|
IDT | Hot Stocks08:37 EDT NRSInsights says April same-store sales increased 6.5% - NRSInsights announced comparative same-store sales results for April 2023. As of April 30, 2023, the NRS retail network comprised approximately 24,000 terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, and tobacco and sundries sellers nationwide, predominantly serving urban consumers. Retail Same-Store Sales Highlights: Same-store sales increased 6.5% from a year earlier. Sales increased 0.1% compared to the preceding month despite April comprising 30 days compared to March's 31 days; Same-store sales in the preceding month had increased 8.0% compared to the year-ago month, and increased 14.0% compared to the preceding month due, in part, to the three additional days in March; For the three months ended April 30, 2023, same-store sales increased 7.9% compared to the three months ended April 30, 2022; The number of items sold during April 2023 increased 6.9% compared to April 2022 but decreased 0.5% compared to March 2023; The average number of transactions per store in April 2023 increased 3.9% compared to April 2022 and increased 1.2% compared to March 2023; A dollar-weighted average of prices for the top 500 items purchased in April 2023 increased 3.1% year over year, a decrease from the 4.3% year-over-year increase in March 2023.
|
FEMY | Hot Stocks08:36 EDT Femasys' FemCerv receives product approval in Canada - Femasys announced that Health Canada, the Public Health Agency of Canada, has granted product approval of FemCerv, the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity. FemCerv captures a tissue sample in a relatively pain-free manner and has the potential to be an improvement over the existing standard of care to diagnose the presence of cancerous cells in a woman's cervix. "We are delighted to gain another product approval in Canada, with FemCerv now available to women throughout all of North America as a more advanced alternative for tissue sampling to detect cervical cancer," stated Kathy Lee-Sepsick, Femasys' founder, president and, chief executive officer. "The current method for detection relies on antiquated tools that can be painful and result in an inadequate or contaminated sample, which may lead to missed diagnosis and unnecessary invasive procedures. Femasys continues to build out our commercial suite of products to bring much-needed technologies to women."
|
BIOS AVRT | Hot Stocks08:35 EDT BioPlus Acquisition, Avertix enter definitive merger agreement - Avertix Medical and BIOS Acquisition Corporation announced that the companies have entered into a definitive merger agreement for a business combination that would result in Avertix becoming a publicly traded company on Nasdaq. The Transaction is expected to close in the second half of 2023. The combined company, which will be named Avertix Medical, Inc., will have an enterprise value of approximately $195 million, and the common stock of the combined company is expected to be listed on Nasdaq under the ticker symbol "AVRT." Avertix is a medical technology company commercializing an implantable device for cardiovascular disease management. The Guardian System is the first and only FDA-approved Class III implantable device designed to detect heart attacks in real-time, including silent and atypical symptomatic heart attacks, providing life-saving alerts to patients and healthcare professionals. Avertix's ALERTS clinical trial showed the Guardian System enables heart attack patients to seek urgent medical attention earlier than patients who relied only on symptoms. The Transaction is expected to provide Avertix access to the necessary financial resources to expand commercially and to continue improving and developing its innovative product, equipping both patients and healthcare providers with lifesaving tools that aim to provide peace of mind. Upon the closing of the Transaction and assuming no redemptions by BIOS' public shareholders, Avertix plans to retain up to approximately $239 million of cash held in the Trust Account on its balance sheet, which would provide financial flexibility and facilitate internal and external growth opportunities. After the closing of the Transaction, and assuming no redemptions, and inclusive of ESOP top up, BIOS' public shareholders are expected to own approximately 50% of the outstanding shares of the combined company, with existing Avertix shareholders owning approximately 29%. The Transaction has been approved by the boards of directors of Avertix and BIOS, and its completion is subject to customary closing conditions, including the approval of BIOS' shareholders and the satisfaction or waiver of a $40 million minimum cash condition. The Transaction is expected to close during the second half of 2023.
|
BLDP | Hot Stocks08:34 EDT Ballard Power awarded 3.6MW of fuel cell systems order from European provider - Ballard Power Systems announced an order for 3.6MW of fuel cell systems from a European provider of clean energy solutions for critical stationary power applications. Ballard expects to deliver 36 x 100 kW systems in 2023 and 2024. allard's fuel cell systems will be integrated into stationary power units which provide zero-emission power for a range of applications, including construction sites, EV charging stations, and data centers. Prior to this new purchase order, Ballard had supplied its customer with approximately 1.2 MW of fuel cells.
|
SBGI | Hot Stocks08:22 EDT Sinclair Broadcast sees FY23 capital expenditures $115M-$120M
|
CVS | Hot Stocks08:20 EDT CVS Health says Q1 had 'robust' cash flow from operations - Says Medicare business one of the strongest growth segments. Sees 12% growth in Medicare Advantage business in 2023. Says growth in retail pharmacy is "notable." Says Signify Health and Oak Street Health acquisitions a "short term impact" to EPS growth. Comments taken from Q1 earnings conference call.
|
WRAP | Hot Stocks08:18 EDT Wrap announces sponsorship of professional networking symposium at PLECET - Wrap Technologies announced that the Company is sponsoring a major networking event during the inaugural Professionalizing Law Enforcement Community Engagement Training, PLECET, National Conference taking place in Atlanta, Georgia, from May 3-6, 2023. The conference brings law enforcement agencies and communities together and hosts police representatives and officers from all 50 states. "Community engagement is one of the most critical and far-reaching challenges facing law enforcement - impacting public safety at every level," said CEO Kevin Mullins. "We're honored to support and participate in this effort by providing demonstrations of BolaWrap, which helps prevent escalation when restraining and individual. Moreover, we look forward to engaging with this group and learning from like-minded law enforcement professionals who prioritize serving their communities effectively. This event comes at a crucial time for communities and law enforcement agencies to come together and create a safer environment that preserves the officers' and communities' safety."
|
RACE DXC | Hot Stocks08:16 EDT Ferrari signs partnership agreement with DXC Technology - Ferrari N.V. (RACE) announces that Ferrari S.p.A., a wholly owned Italian subsidiary, has entered into a multi-year partnership agreement with DXC Technology (DXC) a global technology services company specialising in the production of advanced digital solutions for the automotive sector. This agreement, which comes into effect as from the fifth round of the Formula 1 season, the Miami Grand Prix, sees DXC Technology become a Scuderia Ferrari Team Partner, with its logo present on the SF-23 cars driven by Charles Leclerc and Carlos Sainz and on the drivers' race suits and helmets. Lorenzo Giorgetti, Ferrari Chief Racing Revenue Officer: "We are delighted to start this partnership with DXC Technology, a company that already provides ICT infrastructures and human machines interfaces for Ferrari's critical systems and with which we will explore further software asset management solutions in the future. With DXC we share values such as business expertise, the search for continuous innovation and dedication to excellence. We look forward to developing this partnership in the years ahead."
|
INGR | Hot Stocks08:15 EDT Ingredion appoints Rob Ritchie as SVP, food and industrial ingredients - Ingredion announced the promotion of Rob Ritchie to senior vice president, food and industrial ingredients, Americas, effective immediately. In this role, Ritchie will lead the Company's food and industrial ingredients businesses for North America and South America. In addition, Ritchie will serve as a member on the Company's executive leadership team and report to Jim Zallie, president and chief executive officer. Ritchie joined the Company in 1996 as an area director in Canada and has held roles of increasing responsibility within the United States, Canada, and Mexico.
|
TNYA | Hot Stocks08:14 EDT Tenaya Therapeutics to present several abstracts at ASGCT annual meeting - Tenaya Therapeutics announced that several abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy, ASGCT, 26th Annual Meeting detailing the company's expanded capabilities for manufacturing and discovering genetic medicines for heart disease. "Tenaya was founded with a singular focus on developing novel medicines for rare and prevalent forms of heart disease. To be a leader in this space requires a sustained commitment to differentiated platform capabilities that enable us to optimize the product profile for our therapeutic candidates and to address new conditions where there is high unmet need," said Faraz Ali, Chief Executive Officer of Tenaya. "The presentations at this year's ASGCT highlight innovations in manufacturing, capsid engineering and gene editing, that support the advancement of our current pipeline and create new opportunities for future pipeline candidates. We look forward to sharing work on additional innovative enabling technologies and genetic medicine programs at future meetings."
|
WSPOF | Hot Stocks08:14 EDT WSP Global acquires LGT, terms not disclosed - WSP Global announced the acquisition of LGT, a Quebec-based building engineering firm. The company said, "lgt provides advisory services in the areas of mechanical engineering, electricity, sustainable development, structural, and civil engineering. It is also recognized for its cutting-edge expertise involving data centres and critical infrastructure. By welcoming lgt, WSP is positioning itself as an essential player in the building engineering consulting field in Quebec, as well as in the highly strategic data centre industry." lgt has over 150 employees at offices in Quebec City, Laval, Rimouski, and Sept-Iles.
|
BGCP | Hot Stocks08:14 EDT BGC Partners sees FY23 Pre-Corporate Conversion Adj. earnings tax rate 5.0%-8.0%
|
ICAD | Hot Stocks08:14 EDT iCAD showcases Breast AI suite at SBI Symposium - iCAD announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world's largest breast imaging conference, the Society of Breast Imaging, SBI, Symposium, taking place May 4-7 in National Harbor, MD. "While mammography screening has improved in recent decades and the introduction of digital breast tomosynthesis offers many clinical advantages, it also creates enormous amounts of data. Processing this volume of data can weigh heavily on radiologists and imaging teams," said Dana Brown, President and CEO of iCAD, Inc. "iCAD's Breast AI Suite offers a 360-degree solution of cancer detection, density assessment, and risk evaluation technologies that are uniquely positioned to address the top challenges clinicians face today. Not only is our solution clinically proven to improve accuracy and efficiency for radiologists reading mammography, it offers critical information about a woman's present and future breast health, which can help clinicians find more interval breast cancers at their earliest stage possible."
|
BWAQ | Hot Stocks08:13 EDT Blue World Acquisition extends deadline for initial business combination - Blue World Acquisition Corporation announced that, it held an extraordinary general meeting and obtained the shareholders approvals for the proposals. At the Shareholder Meeting, the shareholder of the Company approved to amend the Company's Amended and Restated Memorandum and Articles of Association to provide that the Company has until May 2, 2023 to complete a business combination, and may elect to extend the period to consummate a business combination up to nine times, each by an additional one-month extension, for a total of up to nine months to February 2, 2024. The shareholders also approved to amend the Investment Management Trust Agreement dated January 31, 2022, by and between the Company and Continental Stock Transfer & Trust Company to provide that the Trustee must commence liquidation of the Company's trust account by May 2, 2023, or, if further extended by up to nine Monthly Extensions, up to February 2, 2024, and the Company's sponsor, Blue World Holdings Limited and/or its designees may make deposit of $0.0295 per public share into the Trust Account for each Monthly Extension. Pursuant to the Company's amended Charter, the Company may extend on monthly basis from May 2, 2023 until February 2, 2024 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust Account. In order to extend the date by which the Company mush complete its initial business combination from May 2, 2023 to June 2, 2023, an aggregate of $194,324 has been deposited into the Company's Trust Account, representing $0.0295 per remaining public share of the Company. The Company issued an unsecured promissory note to the Sponsor to evidence such payment.
|
XWEL | Hot Stocks08:11 EDT Xwell unveils automated massage chairs at XpresSpa locations - XWELL in partnership with WellnessSpace Brands and Human Touch, manufacturers of hands-free massage equipment, have installed fully autonomous and customizable massage chairs at seven XpresSpa locations in the United States. "We are excited to expand the use of these transformative massage chairs across our business for the benefit of people on the go," said XWELL Chief Executive Officer Scott Milford. "Together with WellnessSpace Brands and Human Touch, we now have yet another tool to provide an oasis from the challenges of modern air travel, supplementing our talented massage professionals. Many guests are taking advantage of these new services which proves that our investment in innovation is paying off, and as our investments in new technology continue to grow, we estimate more than $1 million in incremental revenue as a result."
|
BIIB LLY | Hot Stocks08:11 EDT Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target - Shares of Biogen (BIIB) are down about 1% near 8 am ET, off their earlier session lows, after competitor Eli Lilly's (LLY) TRAILBLAZER-ALZ 2 Phase 3 study showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Shares of Eli Lilly are up $24.30, or 6%, to $428.50 in pre-market trading following the report.
|
IMMX | Hot Stocks08:10 EDT Immix Biopharma announces early interim clinical trial data on IMX-110 - Immix Biopharma announced positive early interim clinical trial data: 100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 antibody tislelizumab combination in the first cohort of patients who received the lowest IMX-110 dose in its ongoing dose escalation 1b/2a clinical trial of IMX-110 + anti-PD-1 antibody tislelizumab, as of the April 14, 2023 data cutoff date. "We are excited to see 100% tumor shrinkage in the very first cohort at the lowest dose of IMX-110 in combination with anti-PD-1 antibody tislelizumab in our ongoing IMMINENT-01 dose escalation trial, especially in patients with advanced colorectal cancer, who have limited treatment options," said Ilya Rachman, MD PhD, CEO of ImmixBio. "These initial results potentially validate the scientific rationale for the promise of IMX-110 to unlock our immune system's ability to fight cancer." Dosing of the first cohort of three advanced metastatic colorectal cancer patients is complete, as of April 14, 2023, for the ongoing Phase 1b portion of the IMMINENT-01 Phase 1b/2a clinical trial investigating IMX-110 in combination with BeiGene / Novartis anti-PD-1 antibody tislelizumab in advanced solid tumors, including colorectal cancer. No dose limiting toxicities have been observed in the first cohort, which means that the trial can now enroll the next cohort of three patients at a higher dose of IMX-110 in combination with anti-PD-1 antibody tislelizumab. Tumor shrinkage was observed in the first two out of two evaluable patients at 2-months.
|
LNZA | Hot Stocks08:09 EDT LanzaTech appoints Aura Cuellar as EVP of Growth, Strategic Projects - LanzaTech Global announced that Aura Cuellar has joined as Executive Vice President, EVP, of Growth and Strategic Projects. Prior to joining LanzaTech, Aura Cuellar most recently served as Vice President of Energy Transition for Shell in the United States.
|
DXC RACE | Hot Stocks08:09 EDT DXC Technology signs agreement with Scuderia Ferrari - DXC Technology (DXC) announced it has signed a multi-year agreement with Scuderia Ferrari, the racing division of Ferrari (RACE), including a commitment to engineer the latest in automotive digital solutions, elevating the performance and driving experience. DXC brings together customized, end-to-end technology to provide engineering solutions that power the automotive industry. DXC is working with Ferrari on a unified and scalable digital cockpit modernizing the in-vehicle information and entertainment system. This will enable a long-term software strategy that can be deployed in Ferrari sports cars produced from 2024 onwards. Together with Scuderia Ferrari, DXC will bring together the latest proven technologies in Formula 1 with the latest in human machine interfaces (HMI). In addition, DXC's logo will appear on the outer halo of the Scuderia Ferrari Formula 1 cars, as well as on the driver race suit, helmet, and other materials, beginning May 5 with the Formula 1 Miami Grand Prix.
|
AQMS | Hot Stocks08:08 EDT Aqua Metals, 6K Energy partner to develop materials for lithium batteries - Aqua Metals announced a partnership to develop the next generation of low-carbon battery materials and plans to establish a long-term agreement for 6K Energy's PlusCAM cathode material manufacturing plant. Both Aqua Metals and 6K Energy share the vision of creating a domestic low-carbon supply chain for critical battery materials and advancing cost-effective production methods for sustainable lithium-ion batteries. The Companies have initiated the partnership with a non-recurring engineering agreement to further develop low-carbon technology for the conversion of critical metals, first virgin and later recycled material, into battery-grade cathode active material precursors, which are essential to 6K Energy's advanced cathode manufacturing. "Aqua Metals believes that the key to sustainable energy lies in leveraging the full potential of recycled materials in manufacturing lithium-ion batteries, building a circular supply chain domestically, and minimizing the environmental impact of the clean energy industry," said Steve Cotton, President & CEO of Aqua Metals. "Our commitment to pioneering low-carbon, closed-loop battery recycling powered by electricity aligns perfectly with 6K Energy's groundbreaking sustainable cathode manufacturing, and our partnership signifies a major step towards U.S. leadership in the next generation of net-zero battery materials and technologies." The Companies plan to co-locate pCAM manufacturing with 6K Energy's PlusCAM factory. PlusCAM will be the world's first UniMelt plasma cathode manufacturing plant, providing low cost, ultra-sustainable production of battery material in the U.S., with production capacity of 13,000 tons per annum.
|
UNVR | Hot Stocks08:07 EDT Univar subsidiary announces exclusive agreement with Solvay - Univar Solutions China, a subsidiary of Univar Solutions, announced a new exclusive agreement with Solvay, expanding the partnership between the two companies for a broad range of lubricant and metalworking fluid additives for multiple markets in Eastern China, including Shanghai, Jiangsu, Zhejiang, Anhui, Hunan, and Jiangxi. The agreement includes high performance specialty additives and components for optimized metal surface cleaning, finishing, and treatment, including surfactants, degreasers, emulsifiers, boosters, and other additives increasingly sought by formulators looking for multifunctional ingredients that demonstrate excellent compatibility with a wide array of processes and applications while mitigating friction and wear.
|
MULN | Hot Stocks08:07 EDT Mullen Automotive provides updates on manufacturing, vehicle programs - Mullen Automotive issues a Company update, including recent highlights and accomplishments for the Company, across manufacturing facilities, energy programs, Bollinger Motors, commercial and consumer EV programs. The Company reports as of April 30, 2023, cash available for operations was $116.1 million. Recent Company Updates: Mishawaka, IN Manufacturing Plant: Home to Mullen FIVE and Bollinger B1 and B2: Commercial vehicle equipment transferred to Tunica, MS facility for commercial Class 1 launch; Commissioning of e-coat and paint facility for readiness to paint early prototype builds; Enterprise data infrastructure including fiber optics, new servers and security systems installed to support volume manufacturing. Tunica, MS Assembly Facility: Home to vehicle assembly for Commercial Class Vans and Trucks; Mullen Class 1 and Class 3 commercial vehicles are assembled in Tunica, MS; In July 2023, the production line for Class 3 will become operational with Class 3 trucks rolling off the line with anticipated deliveries and revenue in August and September 2023; Addition of trim and chassis assembly lines to accommodate new models; New capital expenditures including Automated Guided Vehicles to transport vehicles through plant, installation of robots, water test booth and end-of-line diagnostics; Enterprise data infrastructure including fiber optics, new servers and security systems installed to support volume manufacturing; Hiring of 35 additional operational team members in support of commercial vehicle production. Bollinger Motors - Oak Park, MI: Class 4 - 6 Commercial Vehicles Bollinger B1 SUV and B2 Pick Up Truck; B4 chassis cab engineering at 90% completion; Vehicle testing of B4 chassis cabs started and on schedule; Restart of B1 SUV program began on March 1, 2023; Conducted January 2023 "Ride Along" event at Oak Park HQ for Alpha 1 vehicle; Showcased B4 at 2023 industry shows: including NTEA Work Truck Show in Indianapolis, IN, and ACT Expo in Anaheim CA, Hired an additional 30 people, mostly engineers, in support of B1 restart and commercial truck programs. Mullen Commercial Vehicle Program - Troy, MI" Class 1 and 3 Commercial Vehicles: The company has received $263 million in purchase orders for Mullen Class 1 and Class 3 EV Vans and Trucks from Randy Marion Automotive Group; Program moves from pre-revenue to expected revenue in August 2023; Commercial product development focused on completing vehicle certifications; Team successfully achieved major milestone in April completing all required FMVSS tests for vehicle crash worthiness and occupant safety validation for Class 1 EV van; Successfully completed customer pilot with Menzies at LA Airport delivering the results expected - over 1,500 miles driven and 100% uptime; First presentation of portfolio at several large 2023 commercial fleet shows - NTEA Work Truck Show in Indianapolis, IN, NAFA in Baltimore, MD, and ACT Expo in Anaheim CA, Announced the availability of the Class 3 pilot program for customers wanting to test the vehicle in specific commercial use-case scenarios; Initial vehicle shipments of Mullen EV Cargo Van to University North Carolina Charlotte and MGT Leasing in March 2023. Mullen Consumer Vehicle Program - Irvine, CA: Mullen FIVE Crossover: Simultaneously developing Mullen FIVE family of vehicles, which includes two trim levels of the FIVE EV crossover and the high-performance Mullen FIVE RS variant; vehicle styling freeze in Q4 2023 and production design of Mullen FIVE and FIVE RS planned for reveal at CES in January 2024; Virtual crash and aerodynamic simulations on track; Finalizing key supplier selection and engagement; Preparations for August 2023 Strikingly Different EV Tour in the works with expanded vehicles joining the planned upcoming tour, including, but not limited to, the Mullen FIVE and FIVE RS and Mullen Commercial Class 1 and Class 3 vehicles; Drivable demonstrator of the new Mullen GT will join the tour in September 2023.
|
RAPT | Hot Stocks08:06 EDT Rapt Therapeutics announces appointment of Listgarten as General Counsel - RAPT Therapeutics announced the appointment of Michael Listgarten as General Counsel. Listgarten has over 25 years of law firm and in-house experience, focused on helping biopharmaceutical companies manage the transition from late-stage clinical development to commercial entities. Most recently, he served as Vice President of Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals, overseeing legal support for the commercial and medical functions, advising on critical transactions, and ensuring compliance with the complex system of laws and regulations governing the biopharmaceutical industry.
|
WING | Hot Stocks08:06 EDT Wingstop sees FY23 high-single digit domestic same store sales growth - Sees FY23 SG&A $85.5M-$87.5M, which includes $2.8M in consulting projects to support the Company's strategic initiatives, previously $82.0M-$84.0M; and stock-based compensation expense of approximately $12.0M-$13.0M previously $11.5M-$12.5M. Additionally, the Company is reiterating the following guidance for 2023 of approximately 240 global net new units; and depreciation and amortization of between $14.0M-$15.0M.
|
PLSE | Hot Stocks08:04 EDT Pulse Biosciences appoints Gansevoort Dunnington, M.D CMO - Pulse Biosciences announced the appointment of Gansevoort "Gan" Dunnington, M.D. as its Chief Medical Officer. "On behalf of the Company, I am thrilled to welcome Dr. Dunnington to the Pulse Biosciences team," said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. "Dr. Dunnington brings a wealth of knowledge, expertise, and experience in the field of cardiothoracic surgery, where he is a leader in pioneering novel less-invasive technologies that improve the lives of patients with atrial fibrillation. We look forward to his leadership and contributions, as we continue to harness the power of nanosecond pulsed field ablation to have a significant and meaningful positive impact on the treatment outcomes of atrial fibrillation, all the while being increasingly patient and physician friendly."
|
DRI RUTH | Hot Stocks08:03 EDT Darden to acquire Ruth's Hospitality Group for $21.50 per share or $715M - Darden Restaurants (DRI) and Ruth's Hospitality Group (RUTH), "jointly announced that they have entered into a definitive merger agreement pursuant to which Darden will commence a tender offer to acquire all of the outstanding shares of Ruth's for $21.50 per share, in an all-cash transaction with an equity value of approximately $715 million. Ruth's, owner and operator of Ruth's Chris Steak House will complement Darden's portfolio of differentiated brands which currently includes Olive Garden, LongHorn Steakhouse, Yard House, Cheddar's Scratch Kitchen, The Capital Grille, Seasons 52, Bahama Breeze and Eddie V's."
|
MEG | Hot Stocks08:03 EDT Montrose Environmental to acquire Matrix Solutions, terms undisclosed - Montrose Environmental announced it has entered into an arrangement agreement to acquire all of the issued and outstanding shares of Matrix Solutions. The transaction, which is subject to, among other things, approval of Matrix shareholders and the Court of King's Bench of Alberta, is expected to close in the second quarter of 2023. Terms of the transaction were not disclosed. Founded in 1984 and headquartered in Calgary, Alberta, Matrix is employee-owned and broadly held with 570 employees, having grown into one of Canada's leading pure-play providers of environmental solutions. The firm advises and supports more than 1100 private and public sector clients from its three main service lines, which include Contaminated Site Assessment, Remediation and Reclamation; Environmental Sciences and Regulatory Planning; and Water Resources Engineering and Management. From its 19 office locations, Matrix serves clients throughout the Canadian provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario.
|
DRI RUTH | Hot Stocks08:02 EDT Darden to acquire Ruth's Hospitality Group for $21.50 per share of $715M - Darden Restaurants (DRI) and Ruth's Hospitality Group (RUTH), "jointly announced that they have entered into a definitive merger agreement pursuant to which Darden will commence a tender offer to acquire all of the outstanding shares of Ruth's for $21.50 per share, in an all-cash transaction with an equity value of approximately $715 million. Ruth's, owner and operator of Ruth's Chris Steak House will complement Darden's portfolio of differentiated brands which currently includes Olive Garden, LongHorn Steakhouse, Yard House, Cheddar's Scratch Kitchen, The Capital Grille, Seasons 52, Bahama Breeze and Eddie V's."
|
AUPH | Hot Stocks08:00 EDT Aurinia Pharmaceuticals: NICE recommends Lupkynis for adults with active LN - Aurinia Pharmaceuticals announced that the National Institute for Health and Care Excellence orNICE, has recommended LUPKYNIS or voclosporin, as an option for treating adults with active lupus nephritis LN class III, IV or V 1, when provided in combination with mycophenolate mofetil MMF . The NICE recommendation applies to England and Wales and follows the recent Medicines and Healthcare Products Regulatory Agency, MHRA, authorization of voclosporin licensed in Great Britain for the treatment of active LN in adult patients. "We are extremely pleased with the NICE recommendation of LUPKYNIS for patients with lupus nephritis. This recommendation follows the earlier approval from the MHRA and further supports access to an important treatment option for those patients. It also emphasizes Aurinia's commitment to providing meaningful therapy for patients experiencing LN in key markets around the world," said Peter Greenleaf, President, and Chief Executive Officer of Aurinia. The NICE appraisal is based on the positive results from the pivotal Phase 3 AURORA-1 study2,3 and the AURORA-2 continuation study4, which demonstrated voclosporin, in combination with MMF and low-dose corticosteroids, led to statistically superior complete renal response rates at 52 weeks compared to MMF and low-dose corticosteroids alone, and maintained stable eGFR over 3 years. The safety profile of voclosporin and MMF and low-dose corticosteroids was generally comparable to MMF and low-dose corticosteroids alone.
|
NKLA | Hot Stocks07:59 EDT Nikola announces sale and delivery of 14 Nikola Tre BEVs - Nikola announced the upcoming sale and delivery of 14 Nikola Tre battery-electric vehicles, or BEVs. The sale is being financed with a long-term lease between Mitsubishi HC Capital America and WattEV. WattEV is building powerful public charging depots to serve fleets of commercial BEVs. WattEV also provides electric trucks as a service, or TaaS, to meet the needs of shippers and fleet operators committed to meeting California's mandates towards zero-emissions. WattEV's first of four charging depots in Southern California will open for service at the Port of Long Beach with access to Interstate 710 and 110 starting in May 2023. Nikola trucks can use the WattEV depots for daily charging. The Nikola Tre BEV is eligible for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project, or HVIP, program funded by the California Air Resources Board, or CARB. With this approval, purchasers of the BEV can now qualify for an incentive valued at $120,000 per truck, and up to $150,000 for drayage fleets, helping to reduce the total cost of ownership for any purchaser operating in the state of California.
|
TW | Hot Stocks07:56 EDT Tradeweb reports April total trading volume of $22.3T, AVD up 4.7% to 1.15T - Tradeweb Markets reported total trading volume for April 2023 of $22.3T . Average daily volume or ADV, for the month was $1.15T, an increase of 4.75% year-over-year YoY. April 2023 Highlights include U.S. government bond ADV was down 11.5% YoY to $120.2B. European government bond ADV was up 9.7% to $36.8bn. Strong retail and institutional U.S. government bond activity was more than offset by declines in wholesale trading as broader treasury market volumes also declined. Higher interest rates continued to drive trading in the retail market. European government bond volumes were supported by strong hedge fund activity amid volatile markets and a pick-up in U.K. Gilts activity.
|
LH | Hot Stocks07:52 EDT Labcorp enters pact to enter relationship with Jefferson Health - Labcorp announced an agreement to enter into a strategic relationship with Jefferson Health, the largest health system serving the greater Philadelphia area and Southern New Jersey. When complete, the arrangements between Jefferson and Labcorp will serve to build academic collaborations around teaching and the development of tests. The relationship will expand the scope and productivity of specialty lab testing that is retained by Jefferson, and will further the academic and research missions of Thomas Jefferson University. Jefferson and Labcorp will work together to establish the Innovation Driving Excellence in Academics, or IDEA, initiative, with a goal of advancing testing capabilities and technologies to improve health outcomes. Additionally, the parties will work together to improve healthcare services for underserved communities in Philadelphia and surrounding areas by using advanced population health digital solutions to deliver enhanced efficiency for patients.
|
EL | Hot Stocks07:51 EDT Estee Lauder falls 12% to $215.20 after cutting FY23 outlook
|
EMR | Hot Stocks07:50 EDT Emerson Electric CFO Frank Dellaquila to retire, Mike Baughman to succeed - Emerson announced that Mike Baughman, vice president, controller and chief accounting officer, has been promoted to executive vice president and chief financial officer, effective May 10. He succeeds Frank Dellaquila, who will be retiring after 32 years with the company. To ensure a transition, Dellaquila will serve as senior advisor to the CEO through Emerson's fiscal year end. Baughman will continue to serve as chief accounting officer for the company.
|
MNTS | Hot Stocks07:50 EDT Momentus signs contract to carry hosted payload for Hello Space, no terms - Momentus has signed an agreement with Hello Space, an internet of things through satellite tech company, to carry a hosted payload of a demo deployer carrying four pocketqube satellites on the Vigoride-7 mission targeted to launch on the SpaceX Transporter-9 mission no earlier than October 2023. Hello Space is a satellite IoT service provider company capable of creating hardware and software for 'pocketqube' satellites that measure 10cm x 5cm x 5cm in size. The company is already a part of the Lora-Alliance network, a global alliance working toward creating a global standard for low-power, long-range, very wide-area IoT networks. The company's deployer, named "Hello Pod" launching with Momentus, is a test product before full-scale manufacturing operations begin. The deployer will carry four pocketqubes. These pocketqube satellites mark the first tranche of an 80-satellite constellation set by Hello Space. "The intersection of lower launch costs, Momentus' ability to flexibly and cost-effectively carry and provide robust on-orbit services, and smarter small satellites is where opportunities and possibilities open up for customers," said Momentus Chief Executive Officer John Rood. "Our hosted payload service will provide Hello Space with the opportunity to focus their resources on their engineering and scientific objectives while entrusting us with their in-space logistics needs like power, data, and communication." "We initiated the design of our deployer in October 2022, and with Momentus, we're looking to be on-orbit in October 2023. Their flexibility and speed were appealing, united with our scalable hi-tech satellite IoT services to offer. We are thrilled about the potential of this great collaboration," said Hello Space Co-founder, Chief Executive Officer Muzaffer Duysal.
|
UBER | Hot Stocks07:44 EDT Uber expanding Shared Rides offering to more cities - Shin-Pei Tsay, Head of Cities & Transportation Policy, wrote in a post in Uber's Newsroom: "Shared Rides are here to stay. At Uber, we are committed to providing you with more affordable, efficient, and sustainable transportation options that serve riders, drivers and cities. That's why we're doubling down on UberX Share, our completely redesigned shared rides offering. After a successful launch last summer, we're excited to announce that we're expanding to Baltimore, Miami, Nashville, Philadelphia, and Washington DC in the coming weeks, with plans to launch even more cities soon." Reference Link
|
ZTEK | Hot Stocks07:42 EDT Zentek provides review of testing conducted on material from Albany Graphite - Zentek, further to its press release dated April 25, 2023 announcing the intention to transfer its Albany Graphite Project located north of Lake Superior and southwest of James Bay in Ontario to its currently wholly-owned subsidiary Albany Graphite Corp., provides a review of some of the past testing conducted on the material produced from the Albany Graphite Project, and key drivers of value since 2015. The Albany Graphite deposit was discovered in 2011 and was identified as a unique hydrothermal graphite deposit formed by an igneous rather than sedimentary process. Flake graphite is formed by the metamorphism of sedimentary rocks rich in organic carbonaceous material. Albany graphite, however, was formed through an igneous process where carbon-bearing fluids separated from an ascending carbon-rich magma and were subsequently precipitated as graphite. Due to this unique igneous origin, Albany Graphite has high performance properties comparable to synthetic graphite. Zentek, under its previous name Zenyatta Ventures Ltd., reported in several previous news releases how Albany Graphite material performed in key metrics including on: October 3, 2013: "Published physics data on electrical resistivity of graphite typically ranges from .003 to .060 ohm-centimetres. Zenyatta's graphite showed a resistivity of .0034 ohm-centimetres for a compressed bulk graphite test bar measuring 50x12x2.4mm. These results are comparable with high grade synthetic graphite and represent a value at the top of the range. The resistivity test was conducted on a random sample of Zenyatta's high purity Albany graphite without any attempt to select particle size or to align the graphite crystals to optimize the test results. These initial test results are very encouraging and indicate that Zenyatta's high purity graphite should be competitive with the best graphite available for a variety of applications including electronic components and batteries." August 12, 2015: "Thermogravimetric Analysis results showed that all Albany graphite samples had high thermal stability under the Ballard standard TGA protocol. Under this protocol most forms of graphite undergo complete thermal decomposition at around 860 degrees C to lose all carbon. On the other hand, Zenyatta's Albany graphite samples only lost 60 - 65% even at 1000 degrees C. The detailed investigation clearly indicated that the Albany graphite exhibits excellent thermal stability, and this can be used advantageously in the sub-components of fuel cells, in particular as the gas diffusion layer material. Also, corrosion resistance is an important requirement for an electrically conductive material like graphite used as a component material in fuel cells. Our testing results revealed that Zenyatta graphite samples of a certain particle size was found to be more corrosion resistant than typical graphite." March 29, 2016: "Zenyatta natural graphite material was prototyped, tested, and compared for key mechanical and electrical properties against Ballard's baseline synthetic graphite in a commercial product platform. Importantly, the properties of Zenyatta's Albany graphite material were all within the specifications needed for high performance of Ballard products in a number of commercial fuel cell applications. The components made from Albany graphite were equivalent to the existing synthetic graphite made components. This is another significant step in the process of qualifying Zenyatta's Albany graphite for existing fuel cell markets in transportation and stationary energy storage. From an environmental and cost advantage, the Ballard report also concluded: Zenyatta graphite provides a clean carbon option for fuel cell components. If Zenyatta's hydrothermal graphite can also be low cost compared to existing synthetic graphite, it will facilitate fuel cell cost reduction and market penetration." Past testing strongly suggest that Albany graphite has the high-performance metrics, such as electrical resistivity, heat tolerance and corrosion resistance, required to compete directly with synthetic graphite in high-end applications like batteries and fuel cells.
|
ARWYF | Hot Stocks07:40 EDT ARway.AI announces trading on OTCQB - ARway is pleased to announce that its common shares are now available for trading in the USA on the OTCQB Venture Market under the stock symbol: ARWYF.
|
WLDPF | Hot Stocks07:39 EDT Wildpack Beverage provides update on status of management cease trade order - Wildpack Beverage is providing an update with its previously announced application to the British Columbia Securities Commission for a management cease trade order as contemplated under National Policy 12-203 - Management Cease Trade Orders, as previously announced in the Company's news release dated April 18, 2023. The Company applied for the MCTO in connection with the Company's anticipated delay in filing its annual financial statements for the year ended December 31, 2022 and related management discussion and analysis and certifications and the CEO and CFO certificates delating to the Financial Statements beyond the prescribed filing deadlines. The MCTO was granted by the BCSC on May 2, 2023, and the Company intends to appoint a successor auditor on or before May 15, 2023, to promptly coordinate the financial audit of the Financial Statements with the successor auditor and expects to file the Required Filings as soon as possible, and in any event no later than June 30, 2023. The MCTO prevents the Company's Chief Executive Officer and Chief Financial Officer from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company. The Company confirms that since the date of the Default Announcement: other than as described above, there has been no material change to the information set out in the Default Announcement that has not been generally disclosed; there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; there has not been any other specified default by the Company under NP 12-203; and there is no other material information concerning the affairs of the Company that has not been generally disclosed. The Company confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements. Additionally, per the news release on April 14, 2023, 1,016,799 Common shares were issued at a deemed price of 0.19 to settle aggregate debt in the amount of USD$141,300 in connection with bonus payments owed to certain current employees.
|
PYR | Hot Stocks07:37 EDT PyroGenesis' Pyro Green-Gas completes integrated cold test for client - PyroGenesis Canada announced that its subsidiary, Pyro Green-Gas has successfully completed the Integrated Cold Test under a previously announced $9.3M project with a key client, one of the world's top diversified steel producers. Under the terms of this project, Pyro Green-Gas has been mandated to supply coke oven gas purification solutions and hydrogen production processes that have combined the potential to allow for the extracting of hydrogen with a 99.999% purity level and improve the client's environmental outcome. With the implementation of Pyro Green-Gas' hydrogen extraction technology, the client would be able to rely on a cleaner energy source for its annealing, galvanizing and acid recovery processes, furthering its efforts to reduce its carbon footprint. "Our achievement in completing this milestone demonstrates our unwavering commitment to delivering innovative solutions that not only meet the needs of our clients but also contribute to a more sustainable future," said P. Peter Pascali, CEO and President of PyroGenesis. "We are excited to be working this renowned industry leader on an important project and are confident that our innovative technology will help them to meet their sustainability goals while improving operational efficiency." The next target milestone, once fully commissioned, is the completion of Performance Acceptance Certificate, which is anticipated to be done before the end of Q3 2023. The parties had previously mutually agreed to extend the duration of the project, which had previously been anticipated to end before 2023
|
IXHL | Hot Stocks07:36 EDT Incannex announces presentation on results from Phase 1 trial of IHL-675A - Incannex Healthcare announced a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.
|
ZVRA | Hot Stocks07:36 EDT Zevra Therapeutics announces FDA acceptance of IND application for KP1077 - Zevra Therapeutics announced the acceptance of an Investigational New Drug, IND, application by the U.S. Food and Drug Administration, FDA, to begin a Phase 1 clinical trial of KP1077 in narcolepsy which is expected to provide additional information regarding the optimal dosing regimen. Zevra plans to initiate the first of several Phase 1 clinical trials of KP1077 in narcolepsy this year. These trials will support both the narcolepsy and idiopathic hypersomnia, IH, clinical development programs. Serdexmethylphenidate, SDX, is the sole active pharmaceutical ingredient in KP1077. "The FDA's acceptance of KP1077's IND for narcolepsy is an important step forward in the advancement of this novel therapy, creating a meaningful opportunity to expand our development efforts into this high-need indication," said Christal M.M. Mickle, Chief Product Development Officer of Zevra. "We have conducted extensive research with SDX, and we believe that KP1077 has the potential to effectively treat both IH and narcolepsy types 1 and 2 with a differentiated safety profile."
|
GUROF | Hot Stocks07:34 EDT Guru Organic Energy becomes official energy drink partner of CEBL - GURU Organic Energy announced it will become the Official Energy Drink Partner of the Canadian Elite Basketball League and the CEBL Championship Weekend for the 2023 season. GURU's sponsorship includes a comprehensive media plan that comprises of in-arena branding, media and broadcast brand advertising and fun-filled activation opportunities at CEBL arenas in Vancouver, Edmonton, Calgary, Saskatoon, Winnipeg, Niagara, Brampton, Ottawa and Montreal. GURU will also become the official presenting partner of the CEBL's Target Score ending. The CEBL is the only FIBA league globally utilizing this rule, ensuring every game ends with the excitement of a made basket.
|
WVE | Hot Stocks07:32 EDT Wave Life Sciences announces upcoming milestones - Anticipated Upcoming Milestones and Events. WVE-N531 for DMD: Initiate dosing in Part B of WVE-N531 potentially registrational Phase 2 clinical trial in 2023; Deliver data from Part B in 2024. WVE-006 for AATD: Submit CTAs for first-in-human study in 2H 2023. WVE-003 for HD: Deliver additional single-dose and multi-dose biomarker and safety clinical data in 2H 2023; The update in expected timing for HD single-dose clinical data is due to a publicly announced cyber-attack that took place at Wave's mHTT assay vendor in April 2023. No Wave data or patient samples were impacted by the attack and Wave remains in close contact with the vendor as they address this issue. WVE-004 for ALS/FTD: Deliver additional single- and multi-dose biomarker and safety clinical data in 1H 2023. Platform and Pipeline: Anticipate virtual investor event to be held in the third quarter of 2023 during which Wave will demonstrate how it is continuing to extend its leadership in RNA editing and share preclinical data on new wholly-owned programs; Advance collaboration activities with GSK, with potential for additional cash inflows in 2023 and beyond
|
NBIX | Hot Stocks07:32 EDT Neurocrine backs FY23 INGREZZA net product sales view $1.67B-$1.77B
|
LFSWF | Hot Stocks07:31 EDT Lifeist's Mikra begins production activities for Chroma protein bar - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences has begun production activities on its new wellness-focused protein bar, "Chroma", ahead of schedule. "Chroma will mark Mikra's third product but its first to offer consumers a healthy alternative nutritional bar packed with cordyceps, free of added sugars, and certified gluten-free and vegan," said Faraaz Jamal, CEO of Mikra and COO of Lifeist. "We are finalizing production activities of a truly delicious and satisfying nutritional bar that maintains a chocolatey consistency with a delightful fudge aroma. We believe that Chroma will attract a broad and diverse health conscience audience and that our grocery-focused formulation will appeal to large brick and mortar chains like Whole Foods Market, small gyms, studios and health-focused shops alike."
|
AVA | Hot Stocks07:29 EDT Avista CFO Mark Thies to retire, Kevin Christie to succeed - Avista Corp. announced that Senior Vice President of External Affairs and Chief Customer Officer Kevin Christie will become CFO, Treasurer and Senior Vice President Regulatory Affairs effective May 11, 2023, after Avista's Annual Meeting of shareholders. Avista's EVP, CFO and Treasurer Mark Thies has decided to retire. Although his daily responsibilities will transition on May 11, 2023, following Avista's Annual Meeting, Mr. Thies will stay on as EVP until his official retirement on October 1, 2023. Also, as part of Avista's latest leadership transitions, Latisha Hill, who has been Vice President of Community and Economic Vitality since 2020, will add Corporate Communications, Customer Service, and Energy Efficiency to her current responsibilities. Her new title will be Vice President of Community Affairs and Chief Customer Officer effective May 11, 2023, following Avista's Annual Meeting.
|
SEOVF AZN | Hot Stocks07:27 EDT Sernova, AstraZeneca enter collaboration for therapeutic cell applications - Sernova (SEOVF) entered into a preclinical research collaboration with AstraZeneca (AZN) to evaluate the use of Sernova's Cell Pouch System in combination with AstraZeneca's novel therapeutic cells. AstraZeneca is exploring the use of Sernova's Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications. Under the terms of the collaboration, AstraZeneca will lead and completely fund the development of the cell technologies and pre-clinical activities in conjunction with Sernova. The discovery work is being funded and conducted at AstraZeneca. The preclinical research outcomes will determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies.
|
ORTX | Hot Stocks07:26 EDT Orchard Therapeutics announces new clinical. pre-clinical data at ASGCT 2023 - Orchard Therapeutics announced six presentations from across its hematopoietic stem cell, HSC, gene therapy platform will be featured at the 26th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT, taking place May 16-20, 2023, in Los Angeles. "Our presence at ASGCT highlights the transformative impact and broad applicability of our platform," said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics. "Taken together, the data from our MPS programs continues to show the potential of a one-time HSC gene therapy to address some of the most severe manifestations of this complex group of multi-system diseases. In addition, we continue to apply the differentiated delivery mechanism of our platform to advance a strategic research pipeline in difficult-to-treat diseases such as NOD2-Crohn's disease, where we will share updated pre-clinical PoC results. With our research collaborators, we also look forward to providing a first-look at pre-clinical results from OTL-204, which is being developed for the potential treatment of FTD caused by heterozygous mutations in the progranulin gene."
|
ASGOF | Hot Stocks07:26 EDT Asante Gold expects to file financial results by late May, receives MCTO - Asante Gold announces that it has applied for, and received, a management cease trade order, MCTO, from the British Columbia Securities Commission pursuant to which the Company will have until June 30, 2023 to file its annual financial statements, and related CEO and CFO certifications, for the years ended January 31, 2023 and January 31, 2022 and its annual information form for the year ended January 31, 2023. The Company expects to complete the Annual Filings by no later than May 31, 2023. As a result of the Company's listing on the Ghana Stock Exchange on June 29, 2022, the Company ceased to be a "venture issuer" for purposes of National Instrument 51-102 and the filing deadline for the Annual Filings accelerated from May 31, 2023 to May 1, 2023.
|
BLDR | Hot Stocks07:25 EDT Builders FirstSource sees FY23 capital expenditures $325M-$375M - Sees FY23 effective tax rate 23%-25%.
|
AKTS | Hot Stocks07:24 EDT Akoustis receives first Wi-Fi 7 design win from enterprise class customer - Akoustis Technologies announced that it has received its first Wi-Fi 7 design win for its patented 5.5 GHz and 6.5 GHz XBAW filter solutions from a leading enterprise class customer. Multiple Akoustis XBAW filters will be used in a multi-user, multiple-in-multiple-out architecture to deliver high-speed data throughput for enterprise-class access points and other applications. The 5.5 GHz and 6.5 GHz allow for use of the UNII 1-3 and UNII 5-8 bands, enabling low interference and superior spectrum utilization. Jeff Shealy, founder and CEO of Akoustis, stated, "We continue to experience robust design win activity across our Wi-Fi 6E, and now our Wi-Fi 7 portfolio of XBAW(R) filter solutions." Mr. Shealy continued, "Working with top-tier, leading companies is the goal of any technology supplier, and we are excited to help this customer deliver the highest quality, highest speed Wi-Fi connectivity moving forward."
|
BABYF | Hot Stocks07:23 EDT Else Nutrition expands distribution to over 600 stores - ELSE NUTRITION HOLDINGS announces that it has expanded its distribution in the Canadian market with Canada's second largest food retailer. The national rollout includes Else Toddler Formula, Kids Shake Vanilla and Chocolate, and Original and Vanilla flavors of Baby Super Cereal.
|
MGA | Hot Stocks07:23 EDT Magna awarded new high-voltage eDrive business with Global OEM - Magna announced it has been awarded a high-volume contract with a Europe-based Global Premium OEM to supply its new eDrive system. The eDrive is planned for 2027 model SUVs/sedans, with production expected to begin in 2026. "The electrified powertrain technologies of the future are being developed today. We are embracing the challenge to innovate and bring to market scalable technology solutions that our customers require," said Diba Ilunga, President Magna Powertrain. "This new business marks an important milestone in our electrification strategy as we continue to consistently pursue new innovations and solutions to drive the rapidly growing EV sector forward." Magna's eDS Mid is a compact, high-speed e-motor that offers a scalable power range from 100 kW to 140 kW, optimized for 800V. As a high-voltage eDrive system for electric AWD applications, it enables fast reconnecting through a new decoupling system and delivers a highly-efficient inverter with Silicon Carbide technology which contributes to best-in-class efficiency, drivability and safety.
|
KMDA | Hot Stocks07:21 EDT Kamada announces U.S. FDA approval of application to manufacture CYTOGAM - Kamada announced that the U.S. Food and Drug Administration, FDA, has approved its application to manufacture CYTOGAM at the Company's facility in Beit Kama, Israel. The FDA approval represents the successful conclusion of the technology transfer process for CYTOGAM from the previous manufacturer, CSL Behring. "The U.S. FDA approval of this application to manufacture CYTOGAM, which was granted within our expected timeline, following a successful on-site inspection by the FDA, represents a significant accomplishment for Kamada. This is the third product, in addition to GLASSIA(R) and KEDRAB(R), to be approved by the FDA for manufacturing at our Israeli site," said Amir London, Kamada's Chief Executive Officer. "Our business continues to leverage the substantial benefits of the acquired portfolio of four FDA-approved IgGs, and we expect additional growth from these important products in 2023 and beyond. We intend to initiate commercial manufacturing of CYTOGAM at our Israeli facility shortly, which will positively impact the facility's utilization and efficiency. Kamada's continued investment in the manufacturing and distribution of CYTOGAM is representative of the Company's commitment to ensuring the ongoing supply and availability of this important medicine to healthcare providers and solid organ transplant patients."
|
MGTA DNTH | Hot Stocks07:11 EDT Magenta Therapeutics, Dianthus enter definitive merger agreement - Magenta Therapeutics and Dianthus Therapeutics announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics, Inc. and trade on the Nasdaq under the ticker symbol "DNTH". In support of the merger, Dianthus has secured commitments for a $70 million private investment in its common stock and pre-funded warrants from a syndicate of healthcare investors led by Fidelity Management & Research Company, Catalio Capital Management, 5AM Ventures, Avidity Partners, Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures and Venrock Healthcare Capital Partners, that is expected to close immediately prior to completion of the merger. With the cash expected from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have approximately $180 million of cash or cash equivalents immediately post-closing. The cash resources are intended to be used to advance Dianthus' pipeline through multiple clinical data catalysts and is expected to fund operations into mid-2026. The merger and related financing are expected to close in the third quarter of 2023. Magenta previously announced a comprehensive review of strategic alternatives in February 2023 and has since completed winding down a majority of its activities and costs associated with its research and development initiatives, including the termination of its lease and the sale of key assets. Pre-merger Dianthus stockholders are expected to own approximately 78.7% of the combined company and pre-merger Magenta stockholders are expected to own approximately 21.3% of the combined company. The percentage of the combined company that Magenta's stockholders will own as of the close of the transaction is subject to adjustment based on the amount of Magenta's net cash at the closing date. Immediately prior to the closing of the proposed merger, Magenta stockholders will be issued contingent value rights representing the right to receive certain payments from proceeds received by the combined company, if any, related to pre-transaction legacy assets. Following the merger, the combined company will be led by Marino Garcia, the current CEO and President of Dianthus Therapeutics, and the current members of the Dianthus management team. Magenta Therapeutics, Inc. will be renamed "Dianthus Therapeutics, Inc." and the corporate headquarters will be co-located in New York, NY and Waltham, MA. The merger agreement provides that the Board of Directors of the combined company will be composed of eight board members, including all six current Dianthus board members and two from Magenta. The transaction has been unanimously approved by the Board of Directors of each company and is expected to close in the third quarter of 2023, subject to customary closing conditions, including, the approvals by the stockholders of each company and other customary closing conditions.
|
EYPT | Hot Stocks07:02 EDT EyePoint expects cash to fund operations into 2H of 2024 - The Company expects the cash, cash equivalents and investments on hand at March 31, 2023 and expected net cash inflows from product sales will enable it to fund current and planned operations into the second half of 2024.
|
BMY | Hot Stocks07:00 EDT Bristol-Myers says EC grants approval for Breyanzi - Bristol Myers Squibb announced that the European Commission has granted approval for Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union member states.
|
EL | Hot Stocks06:57 EDT Estee Lauder cites headwinds facing Asia travel retail for lowered FY outlook - CEO Freda said, "As the shape of recovery from the pandemic for Asia travel retail comes into better focus, it is proving to be both far more volatile than we expected and more gradual relative to what we experienced in other regions. We are, therefore, lowering our organic sales and EPS outlook for fiscal 2023 to reflect significantly greater headwinds in our fourth quarter than we expected in February." Freda concluded, "While we work through the serious but we believe temporary headwinds facing Asia travel retail, we are encouraged by the strong momentum in the rest of our business. Indeed, consumer demand is robust for our diverse portfolio of brands in developed and emerging markets around the world, evidenced in both organic sales growth and retail sales trends, which drives our confidence in the long-term. What is more, we are thrilled to have acquired the TOM FORD brand last week and are optimistic about its promising growth opportunities."
|
MLTX | Hot Stocks06:52 EDT MoonLake Immunotherapeutics, SHL Medical announce collaboration - MoonLake Immunotherapeutics announced that it has signed a collaboration agreement with SHL Medical to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake's Nanobody sonelokimab. SHL Medical will use its market-proven Molly modular platform technology to develop the autoinjector and provide its device development expertise, assembly guidance, and production competencies to support the drug-device project. A total of 17 combination products that leverage the Molly autoinjector technology have been approved in at least 69 countries, enabling home treatment in a wide range of therapeutic areas that require injectable medicines.
|
EL | Hot Stocks06:49 EDT Estee Lauder expects organic net sales to return to growth in the fourth quarter - The company expects organic net sales to return to growth in the fourth quarter, reflecting continued momentum of post-COVID recovery growth in nearly all markets globally. The impacts from the ongoing pressures in Asia travel retail, driven primarily by risks associated with the volatile and slower than originally anticipated pace of recovery, are expected to partially offset the growth in other markets.
|
CNC | Hot Stocks06:46 EDT Centene to sell Apixio, terms undisclosed - Centene announced that it has signed a definitive agreement to sell Apixio, an artificial intelligence platform that enables value-based care, to New Mountain Capital, a growth-oriented investment firm with more than $37B in assets under management. Centene acquired Apixio in December 2020. With a patented data science infrastructure, Apixio analyzes structured and unstructured data to develop high-fidelity patient health profiles and support value-based care programs. The transaction is subject to customary closing conditions, including regulatory approvals. The company expects the transaction to be neutral to 2023 adjusted EPS.
|
GTHX | Hot Stocks06:43 EDT G1 Therapeutics sees FY23 COSELA net revenue $50M-$60M - G1 today reiterated its year 2023 net revenue guidance. The Company expects to generate between $50M-$60M in COSELA net revenue in 2023. G1's product revenue guidance was initially provided in its fourth quarter and FY22 financial results and business update, and is based on expectations for continued acceleration of sales performance of COSELA in the U.S.
|
IMGN | Hot Stocks06:43 EDT ImmunoGen reports 'positive' results from Phase 3 MIRASOL trial - ImmunoGen announced positive top-line data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE compared to chemotherapy in patients with folate receptor alpha-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the ompany plans to submit a Marketing Authorization Application in Europe and a supplemental Biologics License Application in the U.S. for the conversion to a regular approval of ELAHERE. Results show statistically significant improvements in PFS, ORR, and OS compared to chemotherapy.
|
CERE | Hot Stocks06:38 EDT Cerevel Therapeutics appoints Ron Renaud as CEO - Cerevel Therapeutics announced the appointment of Ron Renaud as president and CEO, and member of the company's board of directors, effective June 12. Renaud will succeed Tony Coles, the current CEO and chairperson of the board of directors, who will continue in his role as chairperson. The company also reported financial results for the first quarter ended March 31 and provided key pipeline and business updates. Renaud brings more than 25 years of experience in evaluating, building, and leading biotechnology companies, with deep expertise in executive leadership, finance, and operations. Renaud's career underscores his commitment to delivering new treatment options to patients in need, cultivating strong company cultures, and advancing innovation in challenging disease areas. Under his leadership as CEO, Renaud led Translate Bio from an early-stage startup to a public company with a leading mRNA technology platform, substantially growing the size and value of the organization through innovative dealmaking and strategic growth opportunities. As the Idenix Pharmaceuticals CEO, he streamlined operations and established a promising portfolio of potential treatments for hepatitis C.
|
TPC | Hot Stocks06:24 EDT Tutor Perini's Fisk Electric awarded $41M contract - Tutor Perini announced that its subsidiary, Fisk Electric Company, has been awarded a subcontract valued at approximately $41M by Robins & Morton, the project's general contractor, for the electrical component of the new Gloria Drummond Patient Tower at the Boca Raton Regional Hospital in South Florida.
|
LSEA | Hot Stocks06:24 EDT Landsea Homes sees FY23 new home deliveries 1,650-2,000 - Sees FY23 Delivery ASPs $540,000-$575,000.
|
LSEA | Hot Stocks06:23 EDT Landsea Homes sees Q2 new home deliveries 450-500 - Sees Q2 delivery ASPs expected to be in the range of $510,000-$520,000; and home sales gross margin of approximately 18%.
|
COTY | Hot Stocks06:23 EDT Coty renews license agreement with Davidoff - Coty is pleased to announce the renewal of their license agreement with Davidoff, extending their long-running partnership beyond twenty years.
|
FC | Hot Stocks06:22 EDT Franklin Covey names Meisha Sherman as Chief People Officer - FranklinCovey announced it has appointed Meisha Sherman to the role of Chief People Officer. Sherman also joins FranklinCovey as a member of its executive team.
|
LLY | Hot Stocks06:19 EDT Eli Lilly TRAILBLAZER-ALZ 2 met primary endpoint, all secondary endpoints - Eli Lilly announced results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale, or iADRS. The primary endpoint of iADRS measures cognition and activities of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events. All secondary endpoints of cognitive and functional decline were also met and showed highly statistically significant clinical benefits with similar magnitude. Based on these results, Lilly will proceed with global regulatory submissions as quickly as possible and anticipates making a submission to the FDA yet this quarter. Lilly will work with the FDA and other global regulators to achieve the fastest path to traditional approvals. TRAILBLAZER-ALZ 2, a randomized, double-blind, placebo-controlled study, evaluated the safety and efficacy of donanemab, an investigational amyloid plaque targeting therapy. The study enrolled people with early symptomatic Alzheimer's disease, or AD, which includes mild cognitive impairment, or MCI, and the mild dementia stage of disease, with the confirmed presence of AD neuropathology, and participants completed their course of treatment with donanemab once they reached a prespecified level of amyloid plaque clearance. Participants in TRAILBLAZER-ALZ 2 were stratified by their level of the brain protein tau, a predictive biomarker for Alzheimer's disease progression. The primary analysis population for which the study was powered was comprised of people with an intermediate level of tau and clinical symptoms of Alzheimer's disease. In this population, the primary endpoint (iADRS) showed 35% slowing of decline, and an important key secondary endpoint showed 36% slowing of decline over 18 months. Additional prespecified secondary analyses showed: 47% of participants on donanemab showed no decline on CDR-SB, a key measure of disease severity at 1 year. 52% of participants completed their course of treatment by 1 year and 72% completed by 18 months as a result of achieving plaque clearance. Participants on donanemab had 40% less decline in ability to perform activities of daily living at 18 months. Participants on donanemab experienced a 39% lower risk of progressing to the next stage of disease compared to placebo. The study also enrolled a smaller number of people with high levels of tau at baseline, representing a later stage of disease progression. Because these participants were predicted to progress more quickly and be less responsive to therapy, the target population for the study was the intermediate tau population. The high tau participants were combined with the intermediate tau population in an additional primary analysis of all participants enrolled. In this combined population, donanemab also demonstrated meaningful positive results across all clinical endpoints, with CDR-SB and iADRS showing 29% and 22% slowing of decline, respectively. The incidence of amyloid-related imaging abnormalities was consistent with the TRAILBLAZER-ALZ Phase 2 study. ARIA is observed with the amyloid plaque clearing antibody class of therapies and is most commonly observed as temporary swelling in an area or areas of the brain or as microhemorrhages or superficial siderosis, in either case detected by MRI. In the overall donanemab treatment group, ARIA-E occurred in 24.0% of treated participants, with 6.1% experiencing symptomatic ARIA-E. ARIA-H occurred in 31.4% in the donanemab group and 13.6% in the placebo group. The majority of ARIA cases were mild to moderate and resolved or stabilized with appropriate management. ARIA is usually asymptomatic, although serious and life-threatening events can occur. In this study, the incidence of serious ARIA was 1.6%, including two participants whose death was attributed to ARIA and a third participant who died after an incident of serious ARIA. Infusion-related reactions occurred in 8.7% of participants with most cases mild to moderate in severity. In addition to slowing cognitive and functional decline in TRAILBLAZER-ALZ 2, donanemab produced significant reductions in brain amyloid plaque levels as early as 6 months after initiating treatment, as observed using amyloid positron emission tomography brain scan, with many patients reaching amyloid levels considered negative for pathology1.
|
MUR | Hot Stocks06:16 EDT Murphy Oil sees Q2 production 173 to 181 MBOEPD - Production for second quarter 2023 is estimated to be in the range of 173 to 181 MBOEPD with 95 MBOPD, or 54 percent, oil volumes. This range includes planned downtime of 6.7 MBOEPD offshore and 3.0 MBOEPD onshore. Murphy forecasts second quarter accrued CAPEX of $320M. Both production and CAPEX guidance ranges exclude NCI.
|
MUR | Hot Stocks06:15 EDT Murphy Oil backs FY23 CapEx view $875M-$1.025B - The company also reaffirms its full year 2023 production range of 175.5 to 183.5 MBOEPD, consisting of approximately 55% oil and 61% liquids volumes.
|
LPX | Hot Stocks06:05 EDT Louisiana-Pacific sees FY23 capital expenditures $330M-$370M - The company said, "Given our current outlook, capital expenditures for 2023, excluding the $80 million paid for the Wawa acquisition, are expected to be in the range of $330 million to $370 million, including $140 million to $160 million for the mill conversions, $120 million to $130 million for sustaining maintenance, and $70 million to $80 million for other strategic growth projects."
|
NUTX | Hot Stocks05:37 EDT Nutex Health opens urgent care center in Southern California - Nutex Health announced the opening of its urgent care center in Southern California. The new urgent care center is located in Alhambra, California, and offers walk-in treatment for everyday illnesses and injury, including advanced offerings such as minor procedures. Nutex Health acquired the two-story building located centrally at 425 West Main Street in Alhambra due to its location close to Associated Hispanic Physicians, or AHP, its independent practice association in Los Angeles. AHP currently has approximately 25,000 patients under capitated risk arrangements with multiple health plans. Nutex Health currently does not own a microhospital in Los Angeles and believes that it can take better and more efficient care of not only AHP's patients but also other patients requiring urgent care services. The administrative office of AHP has also been moved from Monterey Park, CA to our building in Alhambra.
|